

3.1.6 - Number of departments with UGC-SAP, CAS, DST-FIST, DBT, ICSSR and other recognitions by national and international agencies during the year times

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Government/Non-Government)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project
Development of laser system and related technologies for utilization in Nuclear and Non-nuclear application areas (VS9/RRR3004, UID No: RRR2024 dated 15 th May 2019); Development and Application of Optical Fibre Sensors.	Dr. S.K. Dixit	DAE	Government	Physical Sciences	2019	70	5 years
Development of laser system and related technologies for utilization in Nuclear and Non-nuclear application areas (VS9/RRR3004, UID No: RRR2024 dated 15 th May 2019); Studies on ultra-high intensity Laser Material interaction.	Dr.J. A. Chakera	DAE	Government	Physical Sciences	2019	400	5 years
Development of laser system and related technologies for utilization in Nuclear and Non-nuclear application areas (VS9/RRR3004, UID No: RRR2024 dated 15 th May 2019); Atom Optics	Dr. Satya Ram Mishra	DAE	Government	Physical Sciences	2019	150	5 years
Development of laser system and related technologies for utilization in Nuclear and Non-nuclear application areas (VS9/RRR3004, UID No: RRR2024 dated 15 th May 2019); Development of various systems for laser applications.	Dr. B. N. Upadhyaya	DAE	Government	Physical Sciences	2019	370	5 years
Development of laser system and related technologies for utilization in Nuclear and Non-nuclear application areas (VS9/RRR3004, UID No: RRR2024 dated 15 th May 2019); Advanced Diode Pumped Laser and Ultra Fast Fibre Laser.	Dr. P.K. Mukhopadhyay	DAE	Government	Physical Sciences	2019	300	5 years
Development of laser system and related technologies for utilization in Nuclear and Non-nuclear application areas (VS9/RRR3004, UID No: RRR2024 dated 15 th May 2019); Development and Application of Fibre Lasers.	Dr. C.P. Singh	DAE	Government	Physical Sciences	2019	100.52	5 years
Development of laser system and related technologies for utilization in Nuclear and Non-nuclear application areas (VS9/RRR3004, UID No: RRR2024 dated 15 th May 2019); Development of Temperature strain for Waste Immobilization Plant (WIP), BARC.	Dr. Ramakanta Biswal	DAE	Government	Physical Sciences	2019	77	5 years
Development of laser system and related technologies for utilization in Nuclear and Non-nuclear application areas (VS9/RRR3004, UID No: RRR2024 dated 15 th May 2019); Atom Optics	Dr.Vibhuti Bhushan Tiwari	DAE	Government	Physical Sciences	2019	50	5 years
Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); X-ray optics, thin film, surface and interface.	Dr. M.H. Modi	DAE	Government	Physical Sciences	2019	60	5 years
Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); Synchrotron Utilization	Dr. Sanjay Kumar Rai	DAE	Government	Physical Sciences	2019	60	5 years

Compilation of data as received from
Dean - Academic of various CI's/oc of HBNI.

5 years
 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); Material characterization	Dr. M K Tiwari	DAE	Government	Physical Sciences	2019	20	5 years
Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); Semiconductor Materials and Devices	Dr.Tarun Kumar Sharma	DAE	Government	Physical Sciences	2019	790	5 years
Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); Semiconductor Materials and Devices	Dr. Vikay Kumar Dixit	DAE	Government	Physical Sciences	2019	23	5 years
Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); Semiconductor Materials and Devices	Dr.Salahuddin Khan	DAE	Government	Physical Sciences	2019	99	5 years
Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); Laser and Functional Materials Development	Dr.Rajeev Bhatt	DAE	Government	Physical Sciences	2019	25	5 years
Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); Laser and Functional Materials Development	Dr. Srinibas Satapathy	DAE	Government	Physical Sciences	2019	18	5 years
Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); Laser and Functional Materials Development	Dr. S. M. Gupta	DAE	Government	Physical Sciences	2019	3	5 years
Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); Laser and Functional Materials Development	Dr.Gurvinderjit Singh	DAE	Government	Physical Sciences	2019	25	5 years
Up-gradation of R&D Facilities and Materials Research for Technological Applications (VS9/RRC/440, UID No.: RRR4003, dated 5 th Sep 2019); Laser Material Processing	Dr. Pankaj Misra	DAE	Government	Physical Sciences	2019	69.12	5 years
Development of high-stability power converters; Upgrades of Indus Accelerators	Dr. Mangesh Balkrishna Borage	DAE	Government	Engineering Sciences	2019	87.1	5 years
Enhancement of Infrastructure Facilities for Superconducting Cavity Development and Testing; FEL and Utilization	Dr. Vinit Kumar	DAE	Government	Physical Sciences	2019	74	3 years
Basic and Applied Research in Biophysics and Material Sciences: Post-transcriptional and post-translational mechanism in regulation of eukaryotic cell cycle progression	Partha Saha	DAE	Government	Life Science	2019	45	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Structural insights on viral and human proteins	Sampa Biswas	DAE	Government	Life Science	2019	8.3	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Structural insights on viral and human proteins	Udayaditya Sen	DAE	Government	Life Science	2019	2	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Structural and functional insights of membrane transporters	H Raghuraman	DAE	Government	Life Science	2019	50	5 Years

Compilation of data as received from Dean,
Academic of various CI's / occ of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Basic and Applied Research in Biophysics and Material Sciences: Mechanism of protein function by molecular dynamics simulation	Subhendu Ray	DAE	Government	Life Science	2019	5	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Development of composite nuclear-plasmonic materials for highly sensitive site specific chemotherapy	Dulal Senapati	DAE	Government	Life Science	2019	23	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Exploration of the activities of DNA repair inhibitors: Future targets to improve cancer therapy	Padmaja Prasad Mishra	DAE	Government	Life Science	2019	19	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Elucidation of regulatory mechanisms upon perturbation of receptor tyrosine kinases in tumors	Debashish Mukhopadhyay	DAE	Government	Life Science	2019	40	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Characterization of mitochondrial fission-fusion in tumorigenesis	Oishee Chakrabarti	DAE	Government	Life Science	2019	21	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Role of nuclear intermediate filaments in regulation of cellular and nuclear stiffness in neoplasia	Kaushik Sengupta	DAE	Government	Life Science	2019	63	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Characterization of the epigenetic signatures in chemo/radio resistant tumors	Chandrima Das	DAE	Government	Life Science	2019	45	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Engineering novel synthetic genetic logic circuits and genetic systems in living E. coli and its application in invading and delivering RNAs into cancer cells.	Sangram Bagh	DAE	Government	Life Science	2019	60	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Characterization of changes in sub-cellular, cellular and systemic metabolome in response to redox and nutritional stress in cancer	Soumen Kanti Manna	DAE	Government	Life Science	2019	43	5 Years
Basic and Applied Research in Biophysics and Material Sciences: Macromolecular interactions for therapeutic interventions	Subhabrata Majumdar	DAE	Government	Life Science	2019	13	5 Years
Factorization of p-adic L-functions	Prof Aprameyo Pal	SERB	Government	Mathematical Sciences	2023	1.37	2 years
Stochastic thermodynamics of active particles and fields	Dr. Debashis Choudhuri	Science and Engineering Research Board	Government	Physical Sciences	2020	1.8	3 years
Raja Raman Fellowship (RRF) Track-I	Dr. Binaya Kumar Panigrahi	Department of Atomic Energy	Government	Physical Sciences	2021	13.5	3 years
Exploring Multiferroicity in Hollandite Type Mn- based Oxide Materials through Experimental and Theoretical Studies	Dr. Saptishi Mandal	Science and Engineering Research Board	Government	Physical Sciences	2022	0.48	3 years
Quantum Information Technologies with Photonic Devices of Interdisciplinary Cyber Physical Systems (ICPS) Programme	Prof. Pankaj Agrawal	Department of Science and Technology	Government	Physical Sciences	2019	4.42	3 years
Collaborative Research Scheme(CRS) Project of UGC-DAE CSR entitle	Dr. Dinesh Topwal	UGC-DAE Consortium for Scientific Research	Government	Physical Sciences	2022	0.57	1 year
Inspire Faculty Fellowship grant	Mr. Somnath Koley	Department of Science and Technology	Government	Physical Sciences	2022	22	5 years

Compilation of data as received from Dean-
Academic of various CI's/Occ of HBNI.

प्र. पा. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०१४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Inspire Faculty Fellowship grant	Dr. Aparajita Mandal	Department of Science and Technology	Government	Physical Sciences	2020	22.36	5 years
Mobility Fellowship	Dr. Kuntala Bhattacharjee	Department of Science and Technology	Government	Physical Sciences	2019	23	4 years
Indigenous Development and Manufacturing of Seamless Tubes of ASTM B983 (ASME Code case: 2702) for High Temperature/Pressure Applications (ASTM project)	Dr. Diptimayee Samantaray, Dr. Anish Kumar	Office of the Principal Scientific Adviser to the Government of India	Government	Engineering Sciences	2020	1950	3 years
Augmentation of sodium loop and hydraulic loops for conducting experiments	Dr. B.K. Sreedhar, Mr. V. Vinod, Mr. Indranil Banerjee, Mr. S. Krishnakumar, Mr. R. Punniyamoorthy, Mr. Satishkumar S, Mr. Piyush Kumar Aggarwal, Mr. Gautam Kumar Pandey	DAE	Government	Engineering Sciences	2019	465	4 Years 4 Months
Component & facility development for testing of fast reactor systems	Dr. B.K. Sreedhar, Mr. Piyush Kumar Aggarwal, Mr. G. Vijayakumar, Mr. Y. V. Nagaraja Bhat, Mr. S. P. Pathak, Mr. Nirmal Kumar, Mr. A. Sudarsana Rao, Mr. Sarat Kumar Dash	DAE	Government	Engineering Sciences	2019	472.25	4 Years 4 Months
R&D on Severe Accident and Sodium Safety	Dr. D. Ponraju, Mr. Sanjay Kumar Das	DAE	Government	Chemical Sciences	2019	362.5	4 Years 4 Months
Development of Improved Sodium Instrumentation and Revamping of I&C system of Experimental Facilities	Dr. B. Babu, Ms. Sylvia J.I, Mr. Vijayakumar G.	DAE	Government	Engineering Sciences	2019	736.5	4 Years 4 Months
Development of Devices for Remote Handling, Robotic Remote Tooling for Reactor Components and In-pile Experiments for FBRs	Mr. Joseph Winston, Mr. Joel Jose, Mr. Mahedara Prabhu, Mr. Taseem	DAE	Government	Chemical Sciences	2019	263.75	4 Years 4 Months
R&D on pyroprocessing, properties of metal fuel and development of lab scale aqueous reprocessing	Dr. N. Sivaraman, Mr. Suddhasattwa Ghosh	DAE	Government	Chemical Sciences	2019	847.5	4 Years 4 Months
Fabrication of sodium bonded metal fuel SA for FBTR and augmentation of radiological facilities	Dr. V. Jayaraman, Mr. T.V. Prabhu	DAE	Government	Chemical Sciences	2019	927.5	4 Years 4 Months
Radiation damage studies on advanced nuclear materials using high energy accelerators	Dr. R. Govindaraj, Dr. Christopher David, Dr. R Rajaraman, Dr. B Sundaravel, Dr. S Amirthapandian, Dr. Sharat Chandra, Dr. S Abhaya, Dr. Anees P,	DAE	Government	Chemical Sciences	2020	866.67	4 Years 6 Months

Compilation of data as received from
Dean - Academic of various CI's/OCC of HBNI.

Development of diamond/thin film hard coatings and their surface and interface investigations	Dr. Sandip Kumar Dhara, Dr. R Ramaseshan, Dr. S Tripura Sundari, Dr. Arun K Prasad, Dr. K Ganesan, Dr. Ramanathaswamy Pandian,	DAE	Government	Physical Sciences	2020	444.44	4 Years 6 Months
Investigation of hard and functional materials under extreme conditions	Dr. Awadhesh Mani, Dr. T R Ravindran, Dr. Nithya Ravindran, Dr. S Ganesamoorthy, Dr. V Sivasubramanian, superannuated Dr. Edward Prabu Amaladass, Dr. T Sathyanarayana Annam, Dr. Vinod K	DAE	Government	Physical Sciences	2020	677.78	4 Years 6 Months
Testing and qualification of in-core, reactor structural and steam generator materials and their weld joints	Dr. R. Divakar, Dr. A. Nagesha	DAE	Government	Physical Sciences	2020	437.5	4 Years 2 Months
Assessment of irradiation behavior of FBR fuels and structural materials	Dr. V. Karthik , Mr. V. Anandaraj	DAE	Government	Engineering Sciences	2020	668.75	4 Years 2 Months
Corrosion Control and Monitoring Technologies	Dr. S. Ningshen , Dr. A. Ravi Shankar	DAE	Government	Chemical Sciences	2020	396.25	4 Years 2 Months
NDE technologies for inspection and structural integrity assessment	Dr. S. Mahadevan , Mr. K. V. Rajkumar	DAE	Government	Chemical Sciences	2020	350	4 Years 2 Months
Investigation of high temperature phase stability, Microstructure development and Characterization of Thermophysical Properties of Indigenous FBR materials	Dr. C. Sudha, Mr. Akash Singh	DAE	Government	Engineering Sciences	2020	200	4 Years 2 Months
Augmentation of Calibration, radiometric, ionizing and non-ionizing radiation facilities	Dr. B. Venkataraman , Ms. M. Menaka, Dr. Kothai Parthasarathy, Dr. B. Arun, Mr. S. Viswanatham, Dr. Pew Basu, Ms. D.N. Sangeetha, Ms. Athira Warriar	DAE	Government	Physical Sciences	2020	676.67	3 Years
Enhancement of radiological surveillance, environmental monitoring and radiological impact assessment studies	Mr. V. Subramanian , Mr. C. V. Srinivas	DAE	Government	Physical Sciences	2020	460	3 Years
QA and QC services to all facilities of IGCAR, FRFCF and other DAE units	Mr. G. Ramesh , Mr. M. V. Kuppusamy	DAE	Government	Chemical Sciences	2020	133.33	3 Years
Upgradation of mandatory radiological dosimetry (TLD, Invivo, invitro and bio-dosimetry) services	Dr. O. Annalakshmi, Mr. Mathiyarasu	DAE	Government	Physical Sciences	2020	180	3 Years
Enhancement of infrastructure towards mandatory HP surveillance, assay, occupational health, Industrial & Fire Safety services	Dr. S. Chandrasekaran , Mr. Shiva Sai Prasad Gogu	DAE	Government	Chemical Sciences	2020	166.67	3 Years
Evaluation of Low Cycle Fatigue (LCF) and Creep-Fatigue Interaction (CFI) properties of Indigenous Alloy 617M	Dr. A. Nagesha	BRNS	Government	Engineering Sciences	2023	14.72	3 Years

Compilation of data as received from Dean.
Academic of various CI's/oc of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Development of real time fiber coupled luminescence dosimetry system for radiation detection applications	Dr.O. Annalakshmi , Mr. R. Ramar	BRNS	Government	Physical Sciences	2022	10.24	2 years
Development of novel efficient $La_{(1-x)}Sr_xMn_{(1-y)}B_yO_{3-\delta}$ (B= Mg, Co) one dimensional perovskite cathode material for low temperature solid oxide fuel cell	Dr. HRUDANANDA JENA	DAE	Government	Chemical Sciences	2023	6.44	3 years
Investigations on Synthesis and Coordination Behaviour of Phosphine Oxides and their Foam Materials for the Separation of Lanthanides and Actinides in the backend of the fuel cycle	Dr C V S Brahmananda Rao	BRNS	Government	Engineering Sciences	1905	10.67	3 years
Development of Functionalized Polymer Monoliths for Fast Separations and Assay of Lanthanides in Uranium and Plutonium Matrix towards Burn-up Measurements on Fast Reactor Fuels	Dr C V S Brahmananda Rao	BRNS	Government	Engineering Sciences	1905	8.67	3 yaers
Design and fabrication of composite hellow fiber membranes using organic cage linked coordination polymers and waste plastic for olefin-paraffin separation	Dr. Bishnu Prasad Biswal	SERB	Government	Chemical Sciences	2022	15.66	2 Years
Ramanujam Fellowship	Dr. Mriganka Mouli Mondal	SERB	Government	Physical Sciences	2022	23.8	5 years
Secattering Amplitudes and Flat Space Holography	Dr. Shamik Banerjee	SERB	Government	Physical Sciences	2022	12.9	5 years
Aberrant interaction of two pore domain leak potassium channels with Amyloid B in modulating neuronal hyperactivity in aizheimer's Disease	Dr. Swagata Ghatak	SERB	Government	Life Science	2022	14.63	2 years
Microcavity enhanced terahertz nonlinearities of topological states: Towards ultrafast spintronics	Dr. Shovon Pal	SERB	Government	Physical Sciences	2022	9.71	2 years
Teachers Associateship for Research Excellence (TARE)	Dr. Pratap Kumar Chhotaray under the mentorship of Dr. Molay Sarkar	SERB	Government	Chemical Sciences	2022	3.35	3 years
Vibrational Signatures of Chirality, Chiral Recognition and Chirality Transfer through novel Nonvovalent Interactions	Dr. Himansu Sekhar Biswal	SERB	Government	Chemical Sciences	2022	12.32	3 years
Unravelling the Atmospheres of Far Away World with Adaptable Planetary Atmoshere Model	Dr. Jayesh M Goyal	SERB	Government	Physical Sciences	2022	15.25	2 years
Graphical indices associated with different central parts of connected graphs	Dr. Kamal Lochan Patra	SERB	Government	Mathematical Sciences	2023	2.2	3 years
Graph Clustering : A Theoretical Perspective	Dr. Aritra Banik	SERB	Government	Mathematical Sciences	2023	2.2	3 years
Novel Recursive Green's function technique in the Fock space & Applications	Dr. Anamitra Mukherjee	SERB	Government	Physical Sciences	2023	2.2	3 years
National Post Doctoral fellowship	Dr. R Arunachalam under the mentorship of Dr. Chidambaram Gunanathan	SERB	Government	Chemical Sciences	2023	10.66	2 years
National Post Doctoral fellowship	Dr. Debkumar Giri (NPDF) under the mentorship of Dr. Raesh Manna	SERB	Government	Mathematical Sciences	2023	10.66	2 years
Can gut microbes influence host sexual selection and speciation: a study using agricultural pest Tribolium castaneum	Dr. Rittik Deb	SERB	Government	Life Science	2023	10.29	2 years
Analytical and numerical analysis of landslide slope stability under non linear prescriptions of frictional strength	Dr. Pathikrit Bhattacharya	SERB	Government	Physical Sciences	2023	2.2	3 years
Linear codes of the symplectic geometry over finite fields of even characteristic	Dr. Binod Kumar Sahoo	SERB	Government	Mathematical Sciences	2023	9.12	3 years

Compilation of data as received from
Dean - Academic of various CI's/oc of HBNI.

National Post Doctoral fellowship	Dr. Jayaseelan Dhakshinamoorthy (NPDF) under the mentorship of Dr. Ajaya Kumar Nayak	SERB	Government	Physical Sciences	2023	10.66	2 years
Stabilization of non-trivial magnetic skyrmions from trivial bubbles by helicity locking in Centrosymmetric magnets	Dr. Ajaya Kumar Nayak	SERB	Government	Physical Sciences	2023	15.04	3 years
INSPIRE Faculty Fellowship	Dr. Mithun Kumar Das	DST	Government	Mathematical Sciences	2023	22	1 years
Lunar Mantle exposed or missed in South Pole Aitken basin-Insights from Chandrayaan-2 IIRS	Dr. Guneshwar Thangjam	Department of Space	Government	Physical Sciences	2023	8.01	3 years
Spin wave dispersions and nanoscale imaging of magnons using Brillouin light scattering spectro-microscopy	Dr. Subhankar Bedanta	SERB	Government	Physical Sciences	2023	2.43	3 years
Predictive Irrigation Recommendations (TIH-IoT Chanakya Fellowship Program 2022-23)	Dr. Subhankar Mishra	TIH Technology Foundation I-HUB	Government	Mathematical Sciences	2023	7.5	10 months
DST CPR on Disaster Management, Energy Transition, and Tribal Education	Dr. Amarendra Das	DST	Government	Applied Systems Analysis	2023	28.24	1 years
Interaction-induced symmetry-protected topological phase transition	Dr. Tapan Mishra	SERB	Government	Physical Sciences	2023	2.2	3 years
Hard probes of QGP at heavy ion collision experiments	Dr. Lusaka Bhattacharya	DST	Government	Physical Sciences	2023	8.53	3 years
Quantum walk of multi-component bosons and its application to study many-body localization	Dr. Tapan Mishra	SERB	Government	Physical Sciences	2023	12.88	3 years
Swarnajayanti Fellowships Scheme - SJF	Prof. Chandrima Das	DST-SERB	Government	Physical sciences	2019	36.99	5 years
Core Research Grant (Individual Centric) - CRG	Prof. Padmaja Prasad Mishra	DST-SERB	Government	Physical sciences	2020	12.86	3 years
Mathematical Research Impact Centric Support (MATRICS) - MTR	Prof. Abhik Basu	DST-SERB	Government	Physical sciences	2020	1.47	3 years
Core Research Grant (Individual Centric) - CRG	Prof. Abhik Basu	DST-SERB	Government	Physical sciences	2022	0.6	3 years
Start-up Research Grant (SRG) - SRG	Prof. Arunava Mukherjee	DST-SERB	Government	Physical sciences	2020	5.95	2 years
Core Research Grant (Individual Centric) - CRG	Prof. A. N. Sekar Iyengar	DST-SERB	Government	Physical sciences	2021	3.46	3 years
Start-up Research Grant (SRG) - SRG	Dr. Debasish Banerjee	DST-SERB	Government	Physical sciences	2022	4.78	2 years
Core Research Grant (Individual Centric) - CRG	Prof. Debasish Mukhopadhyay	DST-SERB	Government	Physical sciences	2022	7.98	3 years
Core Research Grant (Individual Centric) - CRG	Prof. Oishee Chakrabarti	DST-SERB	Government	Physical sciences	2022	9.25	3 years
Start-up Research Grant (SRG) - SRG	Prof. Subhabrata Majumder	DST-SERB	Government	Physical sciences	2021	8.76	2 years
Teachers associateship for research excellence (TARE) - TARE	Dr. Sudip Mukherjee	DST-SERB	Government	Physical sciences	2022	1.12	3 years
Teachers associateship for research excellence (TARE) - TARE	Dr. Anwesha Sarkar	DST-SERB	Government	Physical sciences	2019	1.12	3 years
National Post Doctoral Fellowship (N-PDF) - NPDF	Dr. Apoorva Bhattacharya	DST-SERB	Government	Physical sciences	2022	5.14	2 years
National Bioscience Award for Career Development (NBACD) - BT-NBACD	Prof. Chandrima Das	DBT	Government	Physical sciences	2020	4	3 years
Medical Biotechnology - BT-MED	Prof. Chandrima Das	DBT	Government	Physical sciences	2019	13.4	3 years
National Bioscience Award, NWBA - BT-HRD-NWBA	Prof. Oishee Chakrabarti	DBT	Government	Physical sciences	2019	1.97	5 years
Ramalingaswami Re-entry Fellowship - RLF	Prof. Subhendu Roy	DBT	Government	Physical sciences	2019	3.47	5 years
India Alliance-DBT Welcome - India Alliance-DBT Welcome	Prof. H. Raghuraman	DBT	Government	Physical sciences	2018	48.59	5 years
India Alliance-DBT Welcome - India Alliance-DBT Welcome	Prof. Subhabrata Majumder	DBT	Government	Physical sciences	2020	13.25	5 years
Raja Ramanna Fellowship - RRF	Prof. Satyajit Saha	DAE	Government	Physical sciences	2019	13.39	3 years
The Indian National Science Academy (INSA) Senior Scientist Programme	Prof. Naba Kumar-Mondal	INSA	Government	Physical sciences	2019	4.08	3 years
The Indian National Science Academy (INSA) Senior Scientist Programme	Prof. Bikas K. Chakrabarti	INSA	Government	Physical sciences	2020	4.6	3 years
The Indian National Science Academy (INSA) Senior Scientist Programme	Prof. Milan Kr. Sanyal	INSA	Government	Physical sciences	2021	3.06	3 years

Compilation of data as received from Dean-
Academic of various CI's OCA of HBNI.

Chanakya PDF I-HUB Quantum Technology Foundation (I-HUB QTF) - Chanakya PDF	Prof. Sankar De	I-HUB QTF	Government	Physical sciences	2022	6.3	2 years
Centre for Millimeterwave Semiconductor Devices & Systems – Contract for Acquisition of Research Services - CMSDS-CARS	Prof. Mrinmay Kumar Mukhopad	DRDO	Government	Physical sciences	2023	1.5	3 years
Pattern of care and survival studies- cervix cancer	Dr. Amita Maheshwari	NCRP, ICMR	Government	Medical & Health Sciences	2006	0.36	19 Years
Pattern of care and survival studies Breast cancer	Dr. Rajesh Dikshit	NCRP, ICMR	Government	Medical & Health Sciences	2006	0.36	19 Years
Pattern of care and survival studies Head and Neck cancer	Dr. Rajesh Dikshit	NCRP, ICMR	Government	Medical & Health Sciences	2006	0.36	19 Years
A randomized trial of concurrent versus sequential Tamoxifen with radiotherapy to assess the extent of pulmonary fibrosis and disease related control and survival in breast cancer patients	Dr. Ashwini Budrukkar	ICMR	Government	Medical & Health Sciences	2007	0.66	15 Years 9 Months 2 Days
Phase II randomized trial comparing neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for locoregionally advanced oesophageal cancer	Dr. C. S. Pramesh	DAE	Government	Medical & Health Sciences	2010	0.87	12 Years 2 Months 6 Days
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel versus Weekly Paclitaxel Plus Weekly Carboplatin in Women with Triple Negative Breast Cancer	Dr. Rajendra Badwe	DAE	Government	Medical & Health Sciences	2009	4.67	14 Years
Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer	Dr. Shalaka Joshi	DAE Capital budget	Government	Medical & Health Sciences	2010	5.33	15 Years
A randomized trial comparing intensity modulated external beam radiation alone vs intensity modulated radiation and brachytherapy for reduction in xerostomia in patients with early staged oropharyngeal cancers	Dr. Ashwini Budrukkar	DAE-CTC	Government	Medical & Health Sciences	2010	4.36	12 Years 8 Months 4 Days
Effect of COX-2 and EGFR suppression on markers of angiogenesis and proliferation in squamous cell carcinoma of oral cavity a prospective randomized study.	Dr. Sudhir Vasudevan Nair	SERB	Government	Medical & Health Sciences	2011	3.12	13 Years
Randomized controlled trial to assess blockade of voltage gated sodium channels during surgery in operable breast cancer	Dr. Rajendra Badwe	DAE	Government	Medical & Health Sciences	2011	5.62	13 Years
Prospective Phase III randomized trial of prostate only or whole pelvic radiotherapy in high risk prostate cancer (POP-RT trial)	Dr. Vedang Murthy	DAE	Government	Medical & Health Sciences	2011	1.66	12 Years
Phase III non-inferiority randomized trial comparing three-weekly Cisplatin versus weekly Cisplatin in combination with radiation therapy in patients with advanced carcinoma of the head and neck	Dr. Vanita Noronha	DAE	Government	Medical & Health Sciences	2012	3.53	13 Years
A Phase III Double Blind Randomized Placebo Controlled study of Trastuzumab as Short Duration Preoperative Therapy in patients with HER2-neu Positive Operable Breast Cancer	Dr. Rajendra Badwe	DAE	Government	Medical & Health Sciences	2012	4.39	12 Years
Randomised controlled trial assessing addition of neoadjuvant and maintenance oral metronomic chemotherapy to standard surgery and adjuvant therapy in Stage III/IV Operable Oral cancers	Dr. Prathamesh Pai	DAE	Government	Medical & Health Sciences	2012	7.25	11 Years
Phase II Randomised Controlled Trial Of Postoperative Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Thyroid Cancers	Dr. Gouri Pantvaidya	DAE	Government	Medical & Health Sciences	2012	1.58	14 Years

Compilation of data as received from
Deans - Academic of various CI's/OEC of MRNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Demographic profile of lung cancer and its treatment in India	Dr. C. S. Pramesh	DAE	Government	Medical & Health Sciences	2012	0.27	11 Years
Comparative study for efficacy and safety of Paclitaxel with Cisplatin/Carboplatin versus 5-Fluorouracil with Cisplatin/Carboplatin in resectable carcinoma esophagus or gastroesophageal junction carcinoma	Dr. Kumar Prabhash	DAE	Government	Medical & Health Sciences	2013	0.36	10 Years 10 Months
Prospective Screening log for patients with recurrent or second primary Head and Neck Cancers referred for re-Radiotherapy.	Dr. Sarbani Ghosh Laskar	DAE	Government	Medical & Health Sciences	2014	0.61	10 Years
Ophthalmic Outcomes After Treatment of Paranasal sinus Tumors	Dr. Shiva Kumar Thiagarajan	DAE	Government	Medical & Health Sciences	2013	0.04	8 Years 3 Months 22 Days
Pilot study to assess the presence of hypoxia related biomarkers in patients with oral cancer	Dr. Gouri Pantvaiddya	DAE	Government	Medical & Health Sciences	2014	5.98	9 Years
Role of electrochemotherapy for head and neck and breast cancers in a palliative setting	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Government	Medical & Health Sciences	2015	0.29	7 Years 7 Months 20 Days
Peripheral T-Cell Lymphoma: Impact of Immunophenotypic subsets, cytogenetic abnormalities, microenvironment and PI3K/NFKB on behavior	Dr. Tanuja Shet	DEPARTMENT OF BIOTECHNOLOGY	Government	Medical & Health Sciences	2017	22.66	6 Years
A prospective study to evaluate the feasibility of hippocampal sparing intensity modulated radiotherapy in preserving neurocognitive functions in adult patients with pituitary adenoma.	Dr. Jayant Goda	DAE	Government	Medical & Health Sciences	2016	0.64	7 Years
Adjuvant Radiotherapy in Early Stage Oral Cancers (AREST) -a prospective randomized control trial	Dr. Sudhir Vasudevan Nair	National Cancer Grid	Government	Medical & Health Sciences	2016	59.77	7 Years
Quality Assurance (QA) Program for Molecular Diagnostic testing in Solid Tumors	Dr. Omshree Shetty	NATIONAL CANCER GRID	Government	Medical & Health Sciences	2017	18.51	6 Years
A phase II trial to study efficacy, toxicity and immunomodulatory effect of Carcitol-S in high grade serous epithelial ovarian cancer at first serological relapse	Dr. Amita Maheshwari	MINISTRY OF AYUSH, CCRAS, GOVT OF INDIA	Government	Medical & Health Sciences	2018	16.4	6 Years
A Double Blinded Phase III Randomized Placebo Controlled Trial to Evaluate the Efficacy of Tranexamic Acid to Reduce Operative Blood Loss in Bone Tumor Patients	Dr. Ashish Gulia	DST	Government	Medical & Health Sciences	2018	1.81	5 Years 6 Months
Prospective study to identify biomarkers of chemoresistance to neoadjuvant chemotherapy and discover targetable pathways in triple-negative breast cancer.	Dr. Sudeep Gupta	DST	Government	Medical & Health Sciences	2018	7.14	6 Years

Compilation of data as received from Dean.
Academic of various CI's/Occ of HBNI.

Esophagectomy Complications Platform and Quality Measures: What is the Contemporary Incidence of Complications at High Volume Esophagectomy Centers?	Dr. C. S. Pramesh	DAE	Government	Medical & Health Sciences	2018	2.36	10 Years
Acupuncture as a modality of treatment for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer-A Phase 3 Randomized Controlled Trial (ABC-CIPN).	Dr. Jyoti Bajpai	DAE	Government	Medical & Health Sciences	2018	0.79	6 Years
Prevalence and predictors of malnutrition and its impact on quality of life and prognosis in patients with hepato-biliary tumors - a prospective study	Dr. Prachi Patil	DAE	Government	Medical & Health Sciences	2018	3.46	6 Years
Prevalence and predictors of malnutrition and its impact on quality of life and prognosis in patients with pancreatic tumours - a prospective study	Dr. Prachi Patil	DAE	Government	Medical & Health Sciences	2018	4.86	6 Years
Establishment of national gall bladder cancer registry	Dr. Mahesh Goel	National Cancer Grid	Government	Medical & Health Sciences	2018	3.13	6 Years
An integrated network analysis to identify genomic alteration profiles of human periampullary cancer	Dr. Shailesh Shrikhande	Department of Biotechnology, Government of India	Government	Medical & Health Sciences	2018	4.04	6 Years
A Double Blind Randomized Controlled Trial of Renal Protective Effects of Normal Saline Plus Placebo Versus Normal Saline Plus Mannitol Prior to Cisplatin Containing Chemotherapy Regimens in Osteosarcoma and other Solid Tumors.	Dr. Jyoti Bajpai	DAE	Government	Medical & Health Sciences	2018	5.74	6 Years
Prevalence of Gallstone diseases in the regions with the high and low incidence of gallbladder cancer: current status and future perspective for gallbladder cancer prevention	Dr. Sharayu Mhatre	DAE	Government	Medical & Health Sciences	2018	13.96	5 Years
Machine learning and Artificial Intelligence Database (MAD) And Tumor Radiomics Atlas Project (TRAP) for Cancer: Imaging Biobank	Dr. Nitin Shetty	DBT	Government	Medical & Health Sciences	2019	173.37	5 Years
Deep Learning neural network based radiogenomics in predicting clinicopathological outcomes in non-small cell lung cancer	Dr. Rajiv Kumar	BIRAC-PREDIBLE HEALTH	Government	Medical & Health Sciences	2018	1.12	6 Years
Genome-Wide Association Study to Identify Role of Genetic Susceptibility in Buccal Mucosa Cancer.	Dr. Sharayu Mhatre	ICMR	Government	Medical & Health Sciences	2018	59.56	5 Years
A phase III randomised trial of metronomic maintenance with oral methotrexate and propranolol versus observation after chemotherapy in relapsed platinum sensitive high grade epithelial ovarian cancer.	Dr. Jaya Ghosh	ICMR	Government	Medical & Health Sciences	2019	27.32	5 Years
Tumor Suppressors and Oncogenes: From Endometrial Cancer Cell Lines to Endometrial Cancer Tissues	Dr. Bharat Rekhi	Indian Council of Medical Research	Government	Medical & Health Sciences	2019	1.25	4 Years 4 Months

Compilation of data as received from
Dean - Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशांक्ता नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

A Phase III Randomized Controlled Trial of Hyperthermic or Normothermic Intraperitoneal Chemotherapy versus No Intraperitoneal Chemotherapy during Interval Debulking Surgery in Patients with Advanced Epithelial Ovarian Cancer - HIPEC or NIPEC	Dr. Amita Maheshwari	TMC-DAE	Government	Medical & Health Sciences	2019	42.23	6 Years
Development and Validation of an Electronic Surveillance System for Surgical Site Infections Developing During Hospital Stay and After Discharge: A Multi-Centric Study	Dr. Sheila Myatra	ICMR	Government	Medical & Health Sciences	2018	5.04	5 Years
In Vitro and In Vivo Functions of Cell Surface Estrogen Receptors (csERs) in the Context of Prostate Cancer.	Dr. Mahendra Pal	DAE-BRNS	Government	Medical & Health Sciences	2019	8.09	4 Years
A Prospective Observational Study of longitudinal assessment of neurocognitive function in patients with 1-4 brain metastases of NSCLC treated with Cranial Irradiation	Dr. Anil Tibdewal	DAECTC	Government	Medical & Health Sciences	2019	2.01	7 Years
The effect of resveratrol and copper on mortality in patients with hematological malignancies presenting with febrile neutropenia and sepsis or septic shock admitted to intensive care unit. A pilot study	Dr. Amol Kothekar	Indian Council of Medical Research	Government	Medical & Health Sciences	2020	1.9	4 Years
Patient perception of 'meaningful benefit' from palliative chemotherapy in metastatic lung cancer - A survey	Dr. C. S. Pramesh	TMC-DAE	Government	Medical & Health Sciences	2020	0.48	4 Years 6 Months
Phase 1 study of safety and feasibility of Ayurvedic oral cannabis preparation in the peri-operative period in oral cavity squamous cell cancer	Dr. Shiva Kumar Thiagarajan	TMC-DAE	Government	Medical & Health Sciences	2020	28.85	3 Years
Growth, Endocrine And Reproductive Late Effects In Long-Term Survivors Of Childhood Cancers: A Prospective Observational Study	Dr. Maya Prasad	DAECTC	Government	Medical & Health Sciences	2020	5.32	5 Years
A randomized controlled trial to evaluate adding a brief psychosocial group intervention to usual care on the initial distress of parents of newly diagnosed children with hematolymphoid cancers	Dr. Jayita Deodhar	DAECTC	Government	Medical & Health Sciences	2020	8.42	4 Years
Assessment of Surgical margins in BCS using Intraoperative imaging Techniques (ASSIST)	Dr. Bhavika Kothari	TMC-DAE	Government	Medical & Health Sciences	2020	1.35	4 Years
A randomized controlled trial to Assess the incidence of lymphedema in women with breast cancer undergoing Sentinel lymph node biopsy or Low axillary sampling. (AISLe)	Dr. Bhavika Kothari	TMC-DAE	Government	Medical & Health Sciences	2020	2.48	4 Years
Role of water pollution in development of esophageal cancer: a case-control stratified by high and low risk regions.	Dr. Rajesh Dikshit	Department of Health Research	Government	Medical & Health Sciences	2020	21.93	3 Years
Evaluation of the role of the immune cell profile in the persistence of minimal residual disease and dynamics of the relapse in childhood T-cell lymphoblastic leukemia: a prospective observational study.	Dr. Prashant Tembhare	ICMR	Government	Medical & Health Sciences	2020	11.64	4 Years

Compilation of data as received from
Dean-Academic of various CI's/oc of HBNI.

Assessment of Prakriti (Ayurvedic body constitution) of patients with Cervical and Ovarian cancers	Dr. Amita Maheshwari	Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH	Government	Medical & Health Sciences	2021	5.21	1 Years 6 Months
Development of a Multi-omics based Neoantigen Discovery Platform to generate Personalized Vaccines for Gliomas	Dr. Sridhar Epari	ICMR	Government	Medical & Health Sciences	2020	9.07	3 Years
Treating children with relapsed ALL with mitoxantrone based protocol- A prospective observational study	Dr. Nirmalya Moulik	DAECTC	Government	Medical & Health Sciences	2020	3.12	5 Years
Intra-operative gross examination versus frozen section for achievement of adequate margin in patients undergoing surgery for oral cavity squamous cell carcinoma: A randomized controlled trial.	Dr. Pankaj Chaturvedi	DAECTC	Government	Medical & Health Sciences	2021	20.97	5 Years
Integration of Extended Immune Monitoring (ExImm) and clinical parameters for early prediction of disease trajectory/progression, treatment planning and prophylaxis to improve COVID-19 prognosis: Immunoprofile Consortium by Indian Council of Medical Research	Dr. Prashant Tembhare	Indian Council of Medical Research (ICMR)	Government	Medical & Health Sciences	2020	39.08	2 Years 6 Months
Radionuclide therapy with ¹⁷⁷ Lu-PSMA plus Abiraterone (with ADT) versus Abiraterone (with ADT) alone in metastatic, hormone-sensitive prostate cancer: a randomized phase 2 trial - REPLASE	Dr. Archi Agrawal	DAECTC	Government	Medical & Health Sciences	2020	34.95	4 Years
Efficacy of Supportive Expressive Group Therapy (SEGT) in Psychological and Spiritual Wellbeing, Body Image and Quality of Life in Young Adult Survivors of Childhood Cancer (YASCC)	Mrs. Savita Goswami	DAECTC	Government	Medical & Health Sciences	2021	2.59	3 Years
Clinicopathological features of Cervical adenocarcinomas: A study for a tertiary cancer referral center from 2010-2015.	Dr. Bharat Rekhi	INTRAMURAL FUNDING	Government	Medical & Health Sciences	2021	1.3	2 Years
Targeting perioperative period in Osteosarcoma by use of Propranolol and Celecoxib with Receptor activator of nuclear factor kappa-B ligand (RANKL) blockade - A phase II randomized controlled study	Dr. Jyoti Bajpai	DAECTC	Government	Medical & Health Sciences	2022	7.52	4 Years 6 Months
A multicenter observational study of candidaemia cases with special reference to Candida auris candidaemia among ICU patients in India	Dr. Sanjay Biswas	ICMR	Government	Medical & Health Sciences	2022	0.66	2 Years 6 Months
Retrospective Evaluation of Immunohistochemical 'Histone modifying' epigenetic underpinnings of Breast carcinomas	Dr. Tanuja Shet	DAECTC	Government	Medical & Health Sciences	2022	6.87	2 Years
Effect of Terlipressin in Patients Undergoing Major Hepatectomies for Liver Cancers: A Prospective Randomized Controlled Phase-III Trial (TerliHep Trial)	Dr. Sohan Solanki	TF (Terry Fox)	Government	Medical & Health Sciences	2021	6.42	4 Years
Development and comparison of different training methods for gynecological brachytherapy skills development: A skills and training methodology development and assessment initiative.	Dr. Supriya Chopra	DST	Government	Medical & Health Sciences	2021	61.6	5 Years
An open label, phase 3 randomized trial to evaluate the role of axillary conservation surgery in breast cancer patients post-neoadjuvant chemotherapy. Short title- Post-chemotherapy Axillary Conservation Surgery (PACS)	Dr. Shalaka Joshi	TMC-DAE	Government	Medical & Health Sciences	2022	35.67	13 Years

Compilation of data as received from
Dean-Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशांकी नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

A single-arm phase II study(DASLOW) to evaluate the ability to maintain molecular response with Reduced dose Dasatinib(70 mg once daily) in patients with De-Novo Philadelphia positive Acute Lymphoblastic Leukemia (Ph+ ALL) after achieving deep molecular response during the intensive phase of treatment	Dr. Hasmukh Jain	TMC-DAE	Government	Medical & Health Sciences	2022	7.95	5 Years
Circular stapled end colostomy creation - A safety and feasibility study	Dr. Avanish Saklani	TMC-DAE	Government	Medical & Health Sciences	2022	2.38	2 Years
A phase III randomized study of first line maintenance Hormonal therapy versus observation in patients with estrogen or progesterone receptor positive High grade epithelial Ovarian cancer after completion of primary treatment with surgery and platinum based chemotherapy(H2O study)	Dr. Jaya Ghosh	TMC-DAE	Government	Medical & Health Sciences	2022	51.47	3 Years
Correlation of O6 -Methyl(Alkyl) Guanine-DNA Methyl(Alkyl) Transferase (MGMT/AGAT) Gene Polymorphisms with Hematological Toxicity of Temozolomide in Adult Diffuse Glioma (MAGENTA) - A Case-Control study	Dr. Tejpal Gupta	DAECTC	Government	Medical & Health Sciences	2022	2.65	2 Years
To establish a ready network of clinical trial units across the National Cancer Grid to promote multi-centric collaborative research in the field of drug-and device development.	Dr. Rajendra Badwe	Biotechnology Industry Research Assistance Council (BIRAC)	Government	Medical & Health Sciences	2022	116.45	3 Years
Lesion detection and dosimetry study with 68Ga PSMA and 177Lu PSMA in metastatic clear cell renal cell carcinoma	Dr. Venkatesh Rangarajan	TMC-DAE	Government	Medical & Health Sciences	2022	1.6	2 Years
An open labelled randomized controlled experimental study to assess the efficacy of honey on mitigating risk of chemotherapy-induced febrile neutropenia (HOMIFEN) in patients of head and neck cancer at tertiary care centre	Mrs. Prathepa Jagdish	DAECTC	Government	Medical & Health Sciences	2022	0.3	1 Years 3 Months
Diagnostic performance of sentinel lymphnode mapping algorithm in early stage endometrial cancer.	Dr. Amita Maheshwari	TMC-DAE	Government	Medical & Health Sciences	2022	2.45	1 Years 6 Months
Dexamethasone along with Physical Activity vs routine care in Cancer Related Fatigue in patients with advanced malignancy-A Randomized controlled Phase III Study	Dr. Vanita Noronha	DAECTC	Government	Medical & Health Sciences	2022	4.64	2 Years
Detection of carbapenemase enzymes in Escherichia coli and Klebsiella pneumoniae from blood culture isolates by phenotypic method (mCIM-PLUS) and confirmation by molecular method (RT-PCR) in cancer patients at a tertiary care hospital	Dr. Sanjay Biswas	DAECTC	Government	Medical & Health Sciences	2022	2.9	6 Months
Burkitt-like lymphoma with 11q aberration - study on incidence and behaviour in Indian patients	Dr. Tanuja Shet	TMC-DAE	Government	Medical & Health Sciences	2022	23.9	2 Years
Depression, Anxiety and Stress in Caregivers of Advanced Cancer Patients during Transition to Best Supportive Care: A Cross-Sectional Study in a Specialist Palliative Care Clinic	Dr. Jayita Deodhar	DAECTC	Government	Medical & Health Sciences	2022	0.1	9 Months
Clinicopathological spectrum of ovarian sex cord stromal tumors and role of FOXL2 in adult granulosa cell tumors of ovary.	Dr. Pabashi Poddar	TMC-DAE	Government	Medical & Health Sciences	2022	8.26	2 Years
Evaluation of HER2/neu status in Endometrial Serous Carcinoma	Dr. Bharat Rekhi	TMC-DAE	Government	Medical & Health Sciences	2022	2.94	2 Years

Compilation of data as received from Dean.
Academic of various CI's/oc of HBNI.

Effectiveness of integrated demonstration program on knowledge and competency skills on IV Cannulation therapy in terms of prevention of Chemotherapy related Intravenous complications among the Nursing Staff from selected hospital.	Mrs. Prathepa Jagdish	DAECTC	Government	Medical & Health Sciences	2022	0.25	11 Months
Dosimetric and Feasibility study of Sparing of Tubarial Salivary Glands in Head and Neck Cancer patients treated with Definitive Radiotherapy, with or without Concurrent Chemotherapy	Dr. Ashwini Budrukkar	TMC-DAE	Government	Medical & Health Sciences	2022	2.31	2 Years
Change in symptom burden, anxiety and depression in patients with advanced cancer admitted in Respite Palliative Care Center: A Prospective observational study	Dr. Shamali Poojary	TMC-DAE	Government	Medical & Health Sciences	2023	0.03	1 Years 6 Months
Validation of Lung-specific Graded Prognostic Assessment Score in Brain Metastases - An ambispective validation study	Dr. Anil Tibdewal	TMC-DAE	Government	Medical & Health Sciences	2023	2.8	5 Years
Feasibility of Oto-acoustic Emission assessment in identification of early and significant ototoxic hearing loss in pediatric cancer patients receiving Cisplatin based chemotherapy	Mr. Jitesh Sahoo	TMC-DAE	Government	Medical & Health Sciences	2023	2.91	2 Years
R&D on Various options of Hydrogen Energy Production.	A K TRIPATHI	DAE	Government	Chemical Sciences	2021	1666.67	3 years
Development of Freeze & ZLD Desalination Technologies and Advanced Membranes	ASIM KUMAR GHOSH	DAE	Government	Chemical Sciences	2021	466.67	3 years
R&D in Chemical sciences for Nuclear, Societal and Environmental Applications like Nuclear Safety such as core catcher materials & iodine chemistry, special biosensors, Security related materials and detector materials etc.	HASSAN P A	DAE	Government	Chemical Sciences	2020	3000	3 years
Isotopes and radiation technologies for industrial and societal applications	KUMAR ABHINAV DUBEY	DAE	Government	Chemical Sciences	2021	1018.67	3 years
Development of Novel Glass and Ceramic Materials	MADHUMITA GOSWAMI	DAE	Government	Chemical Sciences	2021	733.33	3 years
R&D in Chemical sciences for Nuclear, Societal and Environmental Applications like Nuclear Safety such as core catcher materials & iodine chemistry, special biosensors, Security related materials and detector materials etc.	PATRA CHANDRA NATH	DAE	Government	Chemical Sciences	2020	3000	3 years
Developmet of system , instrumentation, detectors, & ASCIs for nuclear , medical, security, agriculture and mega science application.	S K JHA	DAE	Government	Chemical Sciences	2021	666.67	3 years
Digital Resources for R&D Support	SOUMYAKANTI ADHIKARI	DAE	Government	Chemical Sciences	2021	1403.33	3 years
Augmentation of facilities for Chemical quality control of Nuclear materials and radiochemical research.	SUPARNA SODAYE	DAE	Government	Chemical Sciences	2019	800	4.5 years
Isotopes and radiation technologies for industrial and societal applications	TIRUMALESH KEESARI	DAE	Government	Chemical Sciences	2021	1018.67	3 years
Irradiation Induced Transformations in Nuclear Materials.	ANIRUDDHA BISWAS	DAE	Government	Engineering Sciences	2022	666.67	3 years
Robotics Automation and remote handling technologies for nuclear and medical applications	D C KAR	DAE	Government	Engineering Sciences	2019	570	5 years
Structural and Thermal Hydraulic Safety Studies for Indian NPP'S	JAYANTA CHATTOPADHYAY	DAE	Government	Engineering Sciences	2020	2700	2 years
India's Participation in Jules Horowitz Reactor Cadarache, France	SAMIRAN SENGUPTA	DAE	Government	Engineering Sciences	2008	972.76	17 years
Processing of Materials and Control of Material Degradation for Nuclear Industry, Zr based, Ni based and Ti based alloys	SANJIB MAJUMDAR	DAE	Government	Engineering Sciences	2019	1316	4 years
Technology Demonstration of Advanced Chemical Processes and equipments for Nuclear Materials	SULEKHA MUKHOPADHYAY	DAE	Government	Engineering Sciences	2021	1166.67	3 years

Compilation of data as received from
Dean - Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ति नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Research on cellular and molecular radiation biology for human health.	ANU GHOSH	DAE	Government	Life Sciences	2021	1161.67	3 years
Augmentation of facilities for enhanced processing of radioisotopes and development of new radiopharmaceuticals & allied products.	ARCHANA MUKHERJEE	DAE	Government	Life Sciences	2021	633.33	3 years
Setting up of a R&D Facilities at KRUSHAK,Lasalgaon for irradiation of fruits and vegetables	BHASKAR SANYAL	DAE	Government	Life Sciences	2021	235	3 years
Setting up of a R&D Facilities at KRUSHAK,Lasalgaon for irradiation of fruits and vegetables	BIBHUTI BHUSAN MISHRA	DAE	Government	Life Sciences	2021	235	3 years
Research in biological systems and their potential biotechnological applications in health and environment.	BIRIJA SANKAR PATRO	DAE	Government	Life Sciences	2021	899.67	3 years
Development of Products, Processes and Technologies for Sustainable Agriculture, including setting up of model Seed Village	J SOUFRAMANIEN	DAE	Government	Life Sciences	2021	1138.67	3 years
Newer application of radiation technology for food security and value addition	R SHASHIDHAR	DAE	Government	Life Sciences	2019	337.5	4 years
Advance Research in Spectroscopy with Synchrotron Radiation, Lasers & R&D on thin film multilayer devices	RAVINDRA D MAKDE	DAE	Government	Life Sciences	2022	1500	3 years
Newer application of radiation technology for food security and value addition	SACHIN NANDKUMAR HAJARE	DAE	Government	Life Sciences	2019	337.5	4 years
Research and Development on anti-cancer drugs, radiation biology and bio-management of waste water.	SANDUR SANTOSH KUMAR	DAE	Government	Life Sciences	2021	370	3 years
Indigenous Scalable Quantum Computing Technology	A K GUPTA	DAE	Government	Physical Sciences	2022	425	5 years
Physics of Materials	ALKA B GARG	DAE	Government	Physical Sciences	2013	700	10 years
Development of Materials, Devices, Analytical Instruments & NDT Techniques for physics Research.	ANIL KUMAR CHAUHAN	DAE	Government	Physical Sciences	2020	2500	3 years
Setting up of a Solar Powered Indian Network for Detection of Radon Anomaly for Seismic Alert (INDRA-SA)	B. K. SAPRA	DAE	Government	Physical Sciences	2019	588.89	4.5 years
Development of Synchrotron and Neutron beamlines, optical multilayer devices, liquid hydrogen test loop and Physics Research.	DINESH VENKATESH UDUPA	DAE	Government	Physical Sciences	2019	1940	5 years
Development of Synchrotron and Neutron beamlines, optical multilayer devices, liquid hydrogen test loop and Physics Research.	HIMANSHU KUMAR POSWAL	DAE	Government	Physical Sciences	2019	1940	5 years
Feasibility studies and Demonstration of laser application in medical isotopes	J PADMA NILAYA	DAE	Government	Physical Sciences	2022	833.33	3 years
Development of Schwarzschild couder Cherenkov Telescope and maintenance of existing facilities of ApSD	K K YADAV	DAE	Government	Physical Sciences	2021	520	5 years
Development of Neutron and Synchrotron Beamlines, Research on Energy Materials, and Investigations of Quantum Spin Phenomena"	MALA N RAO	DAE	Government	Physical Sciences	2021	1548.75	4 years
Augmentation & Upgradation of INDUS beamlines (PX/ECXRD/IR), high pressure , spectroscopic experimental facilities	NANDINI GARG	DAE	Government	Physical Sciences	2022	1166.67	3 years
Research & Development on surface modification using beams & plasma technologies for nuclear & societal applications	RAJIB KAR	DAE	Government	Physical Sciences	2022	286.67	3 years
Upgrading of Environmental Survey laboratories at NPP and DAE Sites.	S ANAND	DAE	Government	Physical Sciences	2019	1114.89	4.5 years

Compilation of data as received from Dean-Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशांती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Development of Neutron and Synchrotron Beamlines, Research on Energy Materials, and Investigations of Quantum Spin Phenomena"	S M YUSUF	DAE	Government	Physical Sciences	2021	1548.75	4 years
Development of Schwarzschild couder Cherenkov Telescope and maintenance of existing facilities of ApSD	VIR KRISHEN DHAR	DAE	Government	Physical Sciences	2021	520	5 years
Diseased biological tissue detection using SERS method	Dr. Mukesh Ranjan	DAE	Government	Physical Science	2018	14.5	3 years
Pesticide detection using SERS method	Dr. Mukesh Ranjan	DAE	Government	Physical Science	2019	9.5	3 years
Board of Research in Nuclear Sciences (BRNS) funded project with UPES, Dehradun	Dr. Sejal Shah	BRNS, DAE	Government	Physical Sciences	2021	18.9	3 years 4 months
Development of a plasma based system for nano-titania production in large quantities and study of its anti-stain, anti microbial properties on textile fabrics	Balasubramanian	DAE	Government	Physical Sciences	2019	7	7 years
Synthesis and characterization of BN nanostructures Technologies for industrial and societal applications	Balasubramanian	DoS / ISRO	Government	Physical Sciences	2020	10.77	3 years
Setting up of Biomedical Waste Treatment Facility along with 200 kg/hr Plasma Pyrolysis System	Alphonsa	DAE	Government	Engineering Sciences	2019	976	6 years
Plasma Sterilization of medical devices and components	Dr. S.K. Nema	DAE	Government	Physical Sciences	1905	334	5 years 4 months
Development of a plasma based system for nano-titania production in large quantities and study of its anti-stain, anti microbial properties on textile fabrics	Dr. S.K. Nema	DAE	Government	Physical Sciences	1905	4.21	5 years 4 months
Development of VLPPS system	Balasubramanian	DAE	Government	Physical Sciences	2019	7	7 years
Development of exhaust gas treatment system	Dr. G. Ravi	DAE	Government	Physical Sciences	2019	2.57	4.5 years
Development of VLPPS system	Dr. G. Ravi	DAE	Government	Physical Sciences	2019	16	4.5 years
DEVELOPMENT OF GRIDDED ION SOURCE FOR APPLICATIONS OF ION THRUSTERS AND MATERIAL RESEARCH(Project)- Fusion Technologies	Dr. Sanjeev Kumar Sharma	DAE	Government	Physical Sciences	2020	140	4 Years
Research Activity(Project)- Tokamaks and Auxiliary Systems RIP-4007-S2-06	Dr. Vipul Laxmidas Tanna	DAE	Government	Engineering Sciences	2020	350	4 years
A HIPIMS technique for dense TiN coating by developing a plasma source with Titanium (Ti) and Cu (copper) metal ions	Ramkrishna Rane	DAE	Government	Physical Sciences	2019	7	6 Years
Study and development of magnetic nanoparticles produced under externally applied electric and magnetic fields	Balasubramanian	DAE	Government	Physical Sciences	2019	33.57	7 years
"Verification of Concurrent Programs in Weak Memory Models"	Dr. Prakash Saivasan	SERB	Government	Mathematical Sciences	2022	2.2	3 years
RELIC "Reconstructing Early and Late events In cosmology"	Dr. Dhiraj Hazra,	DST	Government	Physical Sciences	2022	2.5	3 years
"Theoretical approaches to the study of condensed phase electron and proton transfer process"	Dr. Charulatha Venkataraman	DST	Government	Physical Sciences	2022	10.24	3 years
M (atching) A(uction) C(ontract) Parameterized Algorithms for Economics and Computation"	Dr. Sushmita Gupta	SERB	Government	Mathematical Sciences	2022	1.4	1 year
"First Pages of intermittent random walk searchers – application to Statistical physics, biological and chemical process"	Dr. Amab Pal	SERB	Government	Physical Sciences	2022	6.09	1 year
"Topology of Adjoint Orbits of Lie Groups"	Prof. Pralay Chatterjee	SERB	Government	Mathematical Sciences	2022	2	1 year
Development of Scientific Infrastructures for Basic and Applied Research: Sub-Project 1. Basic and Applied Research in Nuclear Science & Allied Areas.	Dr. Sarmistha Bhattacharyya	DAE	Government	Physical Sciences	2020	602	3 years
Development of Scientific Infrastructures for Basic and Applied Research:Sub-Project 2. Computing and Automation for Basic & Applied Research.	Dr. Sarbajit Pal	DAE	Government	Engineering Sciences	2020	485	3 years

Compilation of data as received from
Dean. Academic of various CI's/oc of HBNI.

Development of Scientific Infrastructures for Basic and Applied Research: sub-Project 3. Development of Detectors and Electronics for X-ray, gamma, neutron imaging, muon and NIR tomography	Dr. Subhasish Chattopadhyay	DAE	Government	Physical Sciences	2020	150	3 years
Three field radical esophagectomy versus two field esophagectomy a prospective randomized controlled trial	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2004	1.98	19 Years
A prospective randomized trial of neo-adjuvant chemotherapy and surgery versus concurrent chemoradiation therapy in patients with stage IB2-IIIB squamous carcinoma of the uterine cervix	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2003	3.32	19 Years 5 Months 20 Days
Phase III trial of surgery followed by conventional radiotherapy (5 fractions/ week) vs concurrent chemoradiotherapy vs accelerated radiotherapy (6 Fractions/week) in high risk, locally advanced stage III & IVA, resectable, squamous cell carcinoma of oral cavity	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2005	2.17	18 Years 5 Months 15 Days
A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer (SOFT Trial)	Dr. Vani Parmar	ETOP - INTERNATIONAL BREAST CANCER STUDY GROUP	Non-Government	Medical & Health Sciences	2005	2.23	18 Years
A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer (TEXT Trial)	Dr. Vani Parmar	ETOP - INTERNATIONAL BREAST CANCER STUDY GROUP	Non-Government	Medical & Health Sciences	2005	1.51	18 Years
Inter laboratory comparison program for immunophenotyping by flow cytometry	Dr. Sumeet Gujral	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2006	0.6	25 Years 5 Months 18 Days
Prospective, collaborative, multi-center multi-national, open cohort study evaluating device associated nosocomial infection rates, extra days, extra costs, antibiotic use, bacterial resistance, mortality, risk factors, infection control process surveillance and cost effectiveness in coronary, medical surgical, mixed, adults, pediatric and newborns intensive care units in Health care settings	Dr. Sheila Myatra	International Nosocomial Infection Control Consortium (INICC)	Non-Government	Medical & Health Sciences	2007	0.06	21 Years 9 Months 22 Days
ALTO-EGF106708- A randomized, multi-center, open-label, phase III study of adjuvant Lapatinib, Trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer	Dr. Sudeep Gupta	NOVARTIS	Non-Government	Medical & Health Sciences	2008	4.21	15 Years
Development of a cohort study to identify and evaluate transitions in lifestyle and risk factors in a rural population with a low cancer disease risk at baseline.	Dr. Rajesh Dikshit	World Cancer Research Fund (WCRF), Center for Global Health Research (CGHR), International Agency for Research on cancer (IARC)	Non-Government	Medical & Health Sciences	2008	9.23	13 Years

Compilation of data as received from Dean.
Academic of various CI's/Occ of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशास्त्री नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Effectiveness and safety of 2 versus 3 doses of HPV Vaccine in preventing cervical cancer: An Indian multi-centre randomized trial	Dr. Sharmila Pimple	International Agency for Research on Cancer, World Health Organization, Lyon, France	Non-Government	Medical & Health Sciences	2008	9.85	18 Years
A randomized trial to evaluate the efficacy and safety of Pemetrexed and Platinum Vs Gefitinib in Non-Small Cell Lung Cancer patients	Dr. Kumar Prabhash	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2010	1.29	12 Years
An Open label, Randomized, Investigator Initiated Multicentric, Phase III Study of Nimotuzumab in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subjects with Locally advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)	Dr. Kumar Prabhash	BIOCON	Non-Government	Medical & Health Sciences	2011	6.32	13 Years
Asia CML Registry (ACR): Web based registry	Dr. Navin Khattry	ASIAN GOVERNMENT RESERACH FUND	Non-Government	Medical & Health Sciences	2011	0.21	13 Years
Protocol No. - D4200000000 : Study Code D4200C00088-A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib	Dr. Vanita Noronha	SANOFI HEALTHCARE INDIA PRIVATE LIMITED (SHIPL)	Non-Government	Medical & Health Sciences	2011	1.18	13 Years
Phase III Study Evaluating Efficacy and Safety of low dose Gemcitabine compared to standard dose Gemcitabine with platinum in advanced non-small cell lung cancer	Dr. Kumar Prabhash	ICON	Non-Government	Medical & Health Sciences	2012	2.61	10 Years
Establishment of audit for collating the data of lung cancer patients receiving systemic therapy with palliative intent in India.	Dr. Vanita Noronha	ICON	Non-Government	Medical & Health Sciences	2012	0.33	11 Years
A Randomized controlled study to evaluate the role of hydroxy-progesterone in prevention of chemotherapy induced neurotoxicity in women with breast cancer	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2013	7.29	11 Years
Protocol No. EMR 062202 559- A prospective, open label, multicentric data collection registry in order to describe treatment choices in management of metastatic colorectal cancer (mCRC) patients with unresectable hepatic and / or extra hepatic disease, across treatment lines (Asian Metastatic Colorectal Cancer Registry)	Dr. Shailesh Shrikhande	Merck PVT Ltd.	Non-Government	Medical & Health Sciences	2013	0.99	9 Years
Protocol No. CABAZL06500- A phase II controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel in recurrent head and neck cancer in India	Dr. Kumar Prabhash	SANOFI	Non-Government	Medical & Health Sciences	2015	7.97	9 Years
A collaborative, multicentre, national trial for newly diagnosed patients with acute lymphoblastic leukaemia (ICiLe-2014)	Dr. Gaurav Narula	Intramural seed & ICMR /NCG	Non-Government	Medical & Health Sciences	2014	3.54	12 Years
Prevalence and predictors of malnutrition and its impact on quality of life in patients with Gastric cancer - a single centre prospective study	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2014	2.33	9 Years

Compilation of data as received from Dean Academic of various CI's/oc of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमि भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
अभियांत्रिकी विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०००१४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Prospective non-randomized study to compare accuracy of clinical examination under anesthesia, axillary ultrasound and histopathological examination for axillary nodal staging in women with clinically NO early breast cancer.	Dr. Shalaka Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	0.44	8 Years 6 Months
Feasibility and implications of thoracoscopic dissection of internal mammary nodes in central and inner quadrant breast cancer	Dr. Sabita Jiwnani	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	3.92	9 Years
Utility of pectoralis major myofascial flap in reducing pharyngocutaneous fistula rates after salvage total laryngectomy.	Dr. Gouri Pantvaidya	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	3.16	9 Years
Phase III randomized trial of high dose chemoradiation and systemic chemotherapy vs systemic chemotherapy alone in patients with unresectable nonmetastatic cholangiocarcinoma	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2015	11.73	9 Years
Survivorship programme for colorectal cancers patients- a randomized study	Dr. Avanish Saklani	MERCK Specialties PVT LTD	Non-Government	Medical & Health Sciences	2015	3.13	8 Years
A Phase III randomized clinical trial to study the radiosensitizing effect of Nelfinavir in Advanced Carcinoma of Cervix. (NELCER Trial)	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	28.25	8 Years
Prospective observational cohort study of advanced Gall bladder cancer patients to study the impact of clinical and molecular characteristics and outcome	Dr. Vikas Ostwal	MERCK PVT LTD	Non-Government	Medical & Health Sciences	2015	4.96	8 Years
Conventional Radiography based Intracavitary Brachytherapy (Standard Arm) versus Magnetic Resonance Image based BrAchyTherapy (Study Arm) in Locally Advanced Cervical Cancers: A Phase III Randomized Controlled Trial (COMBAT - Cervix Trial)	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	16.27	9 Years
Post-Mastectomy Radiation Therapy in High Risk, Node Negative women with Early Breast Cancer (PMRT-NNBC)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	13.31	12 Years
Radiation Dose Optimization in Diffuse large B- cell Lymphoma - A Randomised Phase III non- inferiority trial.	Dr. Jayant Goda	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	8.36	8 Years
Biological effect of low and high dose radiation exposure on human peripheral blood mononuclear cells and tumour tissues of cancer patients: a prospective in-vivo study	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	66.36	6 Years
Assessment of changes in hypoxia related biomarkers during surgery in resectable non-small cell lung cancer	Dr. Sabita Jiwnani	DAE-TMH TRANSCRIPTOME SEQUENCING STUDY PLAN 2712	Non-Government	Medical & Health Sciences	2016	5.16	7 Years
Protocol No. RI-02-003- Reditux TM Registry to compare Effectiveness, Safety and Resource Utilization of Reditux vs. the Reference Medicinal Product to treat Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia in Routine Clinical Practice	Dr. Manju Sengar	DR.REDDYS LAB/Phamax Analytic Resources Pvt Ltd	Non-Government	Medical & Health Sciences	2016	4.08	8 Years
Perioperative therapy (preop chemo v/s CTRT) in locally advanced gall bladder cancers (POLCA-GB)	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	8.79	8 Years
Performance of HPV DNA Test in presence of co-infection with common RTIs	Dr. Sharmila Pimple	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	1.03	6 Years 6 Months

Compilation of data as received from Dean-
Academic of various CI's/OCC of HBNI.

Randomized trial of effect of two fractionation schedules of Adjuvant Radiation following Immediate Autologous Breast Reconstruction (ARIA-BR) on Toxicity and Patient Reported Outcome Measures.	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	5.11	8 Years
Scalp Cooling for the prevention of chemotherapy induced alopecia in breast cancer from a tertiary care cancer center in India	Dr. Jyoti Bajpai	Access Devices	Non-Government	Medical & Health Sciences	2016	1.88	8 Years
Metronomic Adjuvant Chemotherapy Evaluation in locally advanced oral cancers post surgery and appropriate adjuvant therapy	Dr. Pankaj Chaturvedi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	8.63	8 Years
Image Texture Analysis in assessing tumour heterogeneity: A tool to predict, prognosticate cancers and individualize radiotherapy.	Dr. Jai Prakash Agarwal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	12.21	8 Years
Low Cost Companion Diagnostic Test for Predicting Benefit of Adjuvant Chemotherapy in ER+ Breast Cancer	Dr. Sangeeta Desai	DST (Indo US, Endowment Fund)	Non-Government	Medical & Health Sciences	2016	20.41	7 Years
A phase III, double blind, Placebo controlled, randomized trial assessing the effect of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumor. (Add Aspirin Study)	Dr. C. S. Pramesh	TATA TRUST	Non-Government	Medical & Health Sciences	2016	156.03	10 Years
Pregnancy Associated Cancer (PAC) Registry to collate data on epidemiology and treatment patterns & outcomes."	Dr. Jyoti Bajpai	Roche Pvt. Ltd	Non-Government	Medical & Health Sciences	2017	0.88	7 Years
Study of the Nephron Sparing Surgeries done at Tata Memorial Hospital	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	0.04	9 Years
A prospective observational study to determine the risk of Hepatitis B viral reactivation in adolescent and adult acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) with Occult Hepatitis B infection (OHBI).	Dr. Hasruxh Jain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	0.31	8 Years
Protocol No. - NA : Image guided intensity modulated External beam Radiotherapy and MRI based adaptive Brachytherapy in Locally advanced Cervical Cancer. EMBRACE-II	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	5.36	9 Years
Efficacy of Bortezomib and Rituximab in newly diagnosed adolescent and adult CD20 positive Philadelphia (Ph) negative Precursor B-cell acute lymphoblastic leukemia: Phase II study	Dr. Manju Sengar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	13.82	6 Years
Clinicohistopathological correlation of esthesioneuroblastoma and assessment of prognostic impact of expression of apoptosis markers cleaved Caspase 3, XIAP, Survivin and proliferative marker Ki-67	Dr. Asawari Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2016	1.36	6 Years 6 Months
Randomized study of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in hepatocellular carcinoma (IAEA study)	Dr. Reena Engineer	IAEA	Non-Government	Medical & Health Sciences	2016	1.34	7 Years
A Feasibility and Safety Study of Single Application Multifractionated High Dose Rate Brachytherapy in Locally Advanced Cervical Cancer	Dr. Lavanya Naidu	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	3.72	7 Years
Evaluation of VEGF expression of tumor cells as a potential prognostic marker in Ewing's sarcoma	Dr. Jyoti Bajpai	Roche Products India Pvt. Ltd	Non-Government	Medical & Health Sciences	2016	8.91	7 Years
A prospective COhort study of breast cancer patients with New bone metastases to estimate QQuality of life, health Economics &Risk of skeletal complications (CONQUER)	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	3.96	7 Years


Compilation of data as received from Dean -
Academic of various CI's/OCC of HBNI.

Protocol No. - I3Y-CR-JPBQ : A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or plus Placebo and to Compare Fulvestrant plus Abemaciclib or plus Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Loco regionally Recurrent or Metastatic Breast Cancer	Dr. Jyoti Bajpai	Eli Lilly and Company India Pvt. Ltd	Non-Government	Medical & Health Sciences	2016	16.61	7 Years
Intensity modulated radiotherapy with IGRT for Post cricoid and upper esophageal cancer: prospective observational study	Dr. Sarbani Ghosh Laskar	IMRT-IGRT/ Rapidarc Inc Ltd (Madison, WI, USA)	Non-Government	Medical & Health Sciences	2017	14.33	6 Years 6 Months
A Situation Analysis of National Radiotherapy Resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes	Dr. Sarbani Ghosh Laskar	IAEA	Non-Government	Medical & Health Sciences	2017	1.5	7 Years
Satisfaction in Patients on Outpatient Radiation Therapy (SPORT study)	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	0.1	6 Years 3 Months
DHANUSH : Docetaxel as radiosensitizer in Head And Neck cancer patients, Unsuitable for cisplatin based chemoradiation	Dr. Vijay Patil	ICON	Non-Government	Medical & Health Sciences	2017	4.93	12 Years
A two arm randomized open label prospective parallel design superiority Phase II multicentric clinical trial to evaluate the efficacy of a doublet second line chemotherapy versus monotherapy in advanced unresectable or metastatic gall bladder cancer progressing on first line chemotherapy (GB-SELECT)	Dr. Anant Ramaswamy	TERRY FOX	Non-Government	Medical & Health Sciences	2017	8.23	7 Years 6 Months
A comparison of clinicopathological profile of non-B non-C hepatocellular cancer (HCC) and Hepatitis B or C related HCC	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	0.03	7 Years
A randomized trial to compare gefitinib plus chemotherapy vs chemotherapy alone in EGFR positive and T790M mutation negative advanced Non-small cell lung cancer patients after progression on first line gefitinib.	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	6.36	5 Years
Protocol No. - GBR 200-301 : A Prospective, Multicenter, Randomized, Double-blind, Parallel group Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when Given in Combination with Paclitaxel in Patients Diagnosed with HER2 Positive Metastatic Breast Cancer	Dr. Shalaka Joshi	ALKEM LABORATORIES LTD	Non-Government	Medical & Health Sciences	2017	8.83	6 Years 6 Months
A clinical trial to test the number of circulating tumor cells (CTCs) captured by the OncoDiscover Liquid Biopsy Technology in peripheral blood samples of Head and Neck cancer patients.	Dr. Pankaj Chaturvedi	ACTORIUS INNOVATIONS AND RESEARCH PVT LTD.	Non-Government	Medical & Health Sciences	2017	0.52	6 Years 6 Months
Effect of Pre Operative Distress Levels on Post Surgical Wound Healing in Head Neck Squamous Cell Carcinoma Patients	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	0.65	5 Years
BIONIC: Big Imaging Data Approach For Oncology in a Netherlands India Collaboration	Dr. Venkatesh Rangarajan	DEITY-Dept of Electronics Govt of India	Non-Government	Medical & Health Sciences	2017	8.85	8 Years
Clinicopathologic Features of Undifferentiated Round Cell Sarcomas of Bone and Soft Tissues	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2017	1.47	5 Years 6 Months

Compilation of data as received from Dean-Academic of various CI's/oc of MBNI.

Reverse swing-M : Repurposing of Mebendazole in recurrent glioblastoma.	Dr. Nandini Menon	Brain Tumor Foundation, ICON CRSF, ICMR	Non-Government	Medical & Health Sciences	2017	8	6 Years
A randomized study to compare gefitinib with bevacizumab vs gefitinib in EGFR mutation positive Non-small cell lung cancer in palliative setting.	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	64.92	5 Years
"Advancing Cancer-care through CANScripT TM Enabled Personalized Treatment (ACCEPT): A non-randomized, investigator initiated, observational trial to measure predictive power of CANScripT TM for chemotherapeutics and targeted therapy in patients with newly diagnosed, locally advanced head & neck cancer and refractory / relapsed triple negative breast cancer"	Dr. Shripad Banavali	Mitra Biotech Pvt. Ltd, Bangalore	Non-Government	Medical & Health Sciences	2018	33.62	6 Years
A cross-sectional feasibility study of a telephonic questionnaire by research nurses for follow-up of locally advanced cervical cancer patients with complete response to treatment	Dr. Lavanya G	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	0.64	6 Years
Phase IIb/III, Placebo-controlled, double-blind randomized clinical trial, using Curcumin and Metformin in patients with previous history of head and neck squamous cell carcinoma, in an attempt to lower the incidence of second primary tumor	Dr. Sudhir Vasudevan Nair	NATIONAL CANCER GRID	Non-Government	Medical & Health Sciences	2018	5.13	6 Years
Evaluating the clinical utility of new immunophenotypic markers in the determination of minimal residual disease in childhood acute myeloid leukemia.	Dr. Prashant Tembhare	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	0.67	6 Years
Pilot study to evaluate the biodistribution & dosimetry of 177Lu - Trastuzumab in HER2 receptor positive metastatic breast carcinoma and its toxicity & efficacy profile	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	20.5	6 Years
CONcurrent versus SEquential Chemo-Endocrine therapy in ER positive and HER2 negative non-metastatic breast cancer (CONSEQuenCE)	Dr. Shalaka Joshi	IM / CSR Fund from Gen. Insu. Co.	Non-Government	Medical & Health Sciences	2018	19.44	10 Years
Protocol No. - MO29872 : A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab compared with Chemotherapy in Patients with Treatment-Naïve Advanced or Recurrent (Stage IIIB not amenable for multimodality treatment) or Metastatic(Stage IV) Non-Small Cell Lung Cancer who are deemed unsuitable for Platinum-Containing therapy	Dr. Kumar Prabhash	Roche Products (India) Pvt. Ltd	Non-Government	Medical & Health Sciences	2017	33.18	6 Years 4 Months
A dosimetric and clinical study of DIBH in Mediastinal Lymphomas: An exploratory observational study	Dr. Jayant Goda	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	4.07	14 Years
Use of PET-CT with Gallium-68 labelled prostate Specific Membrane Antigen in the Diagnosis and Follow-up of patients with Prostate Cancer	Dr. Archi Agrawal	IAEA	Non-Government	Medical & Health Sciences	2018	3.02	4 Years 6 Months
Utility of MRI in detecting peritoneal metastases in gastric cancer patients with negative CECT abdomen	Dr. Akshay Baheti	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	1.13	6 Years
Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children with Acute Lymphoblastic Leukemia: A Pilot Study	Dr. Maya Prasad	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	10.2	6 Years

Compilation of data as received from Dean-Academic of various CI's/Occ of HBSNI.


 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०१४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - I3Y-MC-JPCF : A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (MonarchE)	Dr. Seema Gulia	Eli Lilly and Company India Pvt. Ltd.	Non-Government	Medical & Health Sciences	2018	21.73	10 Years
A randomized clinical trial evaluating the efficacy and safety of the addition of postoperative chemoradiation versus observation in patients with high-risk esophageal squamous cell carcinoma following surgery	Dr. Devayani Niyogi	CREST Welfare Fund	Non-Government	Medical & Health Sciences	2019	25.03	12 Years
Protocol No. - D419CC00002 : A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA).	Dr. Vikas Ostwal	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2018	10.24	4 Years
A Phase 2 randomized controlled trial to evaluate the role of modified C.O.M.B.A.T maintenance regimen in children with high risk medulloblastoma	Dr. Girish Chinnaswamy	Terry Fox foundation	Non-Government	Medical & Health Sciences	2018	11.68	5 Years
Precision medicine and Malnutrition- A Model based approach to dose chemotherapy in pediatric patients with malnutrition	Dr. Girish Chinnaswamy	Terry Fox Foundation	Non-Government	Medical & Health Sciences	2018	28.82	6 Years
Prevalence of MMR status in gallbladder cancer (GBC) treated with palliative intent and its correlation with response to chemotherapy and survival.	Dr. Vikas Ostwal	Intramural and Extramural grant-unrestricted educational grant from Cadila healthcare limited	Non-Government	Medical & Health Sciences	2018	2.91	6 Years
A randomized phase 2/3 trial of Rosuvastatin with neo-adjuvant chemo-radiation in patients with rectal cancer	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	17.74	7 Years
Introduction of a novel, cost effective, multigene panel for NSCLC patients - A pilot project	Dr. Rajiv Kumar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	34.48	6 Years
Effect Of Pre-Operative Transarterial Embolisation On Circulating Tumor Cells And Recurrence In Hepatocellular Carcinoma	Dr. Mahesh Goel	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3.43	4 Years
Multi-Centric Clinical Trials of Indigenous TKP 2.4: Implant and Pilot Production of TKP 2.4	Dr. Ashish Gulia	Non-ferrous Materials Technology Development Centre, Hyderabad	Non-Government	Medical & Health Sciences	2019	85.58	5 Years
Protocol No. - WO40242 : A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-Pd-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of The Head And Neck	Dr. Kumar Prabhash	Roche Products (India)	Non-Government	Medical & Health Sciences	2018	20.25	7 Years

Compilation of data as received from
Dean - Academic of various CI's/OCC of HBNI.

Prabhakar

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशासनिक विद्यालय परिसर, अणुशांक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - SII-qHPV/IN-02 : A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil®)	Dr. Sharmila Pimple	Serum Institute of India Pvt. Ltd, Hadapsar, Pune (Sponsor)	Non-Government	Medical & Health Sciences	2018	24.95	5 Years 9 Months
Protocol No. - 19214 : A phase IV study to investigate the safety and efficacy of regorafenib in Indian patients with metastatic colorectal cancer (mCRC)	Dr. Vikas Ostwal	Bayer AG, D-51368 Leverkusen, Germany	Non-Government	Medical & Health Sciences	2018	14.58	6 Years
Docetaxel or Cisplatin radiosensitizer in Head and Neck cancer patients for curative or adjuvant chemoradiation	Dr. Kumar Prabhash	Oncology Care Associates, ICON Trust	Non-Government	Medical & Health Sciences	2018	3.85	8 Years
Feasibility Of Magnetic Resonance Image Based Target Delineation In Radical High Dose Rate Interstitial Brachytherapy For Early Oral Cavity Cancers: A Pilot Study	Dr. Ashwini Budrukhar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	0.28	5 Years
Protocol No. - ECTS/16/002 : A multicentric open label phase II safety and efficacy study of ormeloxifene in tamoxifen resistant metastatic/recurrent breast cancer patients.	Dr. Sudeep Gupta	HLL Lifecare Limited	Non-Government	Medical & Health Sciences	2018	9.94	5 Years
Prospective cohort study to determine the association of pre-operative nutritional status with 90 days morbidity among patients undergoing Radical cystectomy or Radical Cysto-Prostatectomy for Muscle Invasive Bladder Cancer	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	0.01	7 Years 6 Months
Carboplatin/paclitaxel versus cisplatin/5-fluorouracil definitive chemoradiotherapy for locoregionally advanced unresectable esophageal and gastroesophageal junction cancer.	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	3.37	10 Years
Protocol No. - 0063-17 : A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.	Dr. Sudeep Gupta	Intas Non-Governmentceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India	Non-Government	Medical & Health Sciences	2018	48.93	5 Years
Pilot Study to standardize the technique of Dynamic Sentinel Lymph Node Biopsy in management of penile cancer patients with clinically normal groin	Dr. Gagan Prakash	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	0.97	4 Years
Biomarker-based optimization of adjuvant therapy in glioblastoma	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	54.18	5 Years
A pilot evaluation of prognostic molecular and serum biomarkers of disease recurrence after chemoradiation in patients with locally advanced cervical cancer from EMBRACE study group (BIO-EMBRACE-1)	Dr. Supriya Chopra	BIOEMBRACE RESEARCH GROUP	Non-Government	Medical & Health Sciences	2019	4.72	5 Years

Compilation of data as received from
Dean - Academic of various CI's / oec of HBNI.

Two arm, triple blinded, randomized placebo controlled, prospective, parallel design Phase II integrated phase III study to evaluate the role of Carica papaya leaf extract (CPLE) in reducing the duration of chemotherapy induced thrombocytopenia and adverse events related to thrombocytopenia	Dr. Vikas Ostwal	CADILA HEALTHCARE LIMITED	Non-Government	Medical & Health Sciences	2019	7.56	5 Years 6 Months
A phase-3 randomized control trial comparing hydroxyurea and L-asparaginase for cyto-reduction in pediatric AML patients presenting with hyperleukocytosis	Dr. Shripad Banavali	SOHN FOUNDATION THROUGH GRAVIS	Non-Government	Medical & Health Sciences	2018	4.72	5 Years
Validation of the Beta Defensin Index (BDI) as a Biomarker for Oral Cancer - India	Dr. Deepa Nair	Case Western University, cleaveland	Non-Government	Medical & Health Sciences	2018	1.64	5 Years 6 Months
A prospective evaluation of a point of care saliva-based detection test based on soluble CD44 (OncAlert) for the presence of disease in a previously untreated oral cavity and oropharynx squamous cell carcinoma.	Dr. Sudhir Vasudevan Nair	Tata Trusts, Vigilant Biosciences	Non-Government	Medical & Health Sciences	2018	3.41	5 Years
A Pilot Study of CONcurrent ChEmotherapy and RadioTherapy in Adjuvant Treatment of Breast Cancer (CONCERT)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	1.33	5 Years
Protocol No. - CACZ885T2301 : A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIa and IIIB (T>5cm N2) completely resected (RO) non-small cell lung cancer (NSCLC)	Dr. Vijay Patil	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical & Health Sciences	2019	12.72	7 Years
Rapid Palliation in Locally Advanced Cervical Cancer: A Phase III randomized trial (RAPPAL Study)	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	14.3	5 Years
Inflammatory Indices in Diffuse Glioma (InDiGo): A Prospective Observational Study	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2018	0.6	6 Years
Human cancer pathology atlas (HCPA) & Machine learning and Artificial intelligence in Pathology (MAP)	Dr. Swapnil Rane	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	294.87	5 Years
Androgen blockade - Is this the missing link between mucinous micro-papillary carcinoma and micro-papillary carcinoma of breast.	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	8.11	5 Years
A Prospective Randomised trial to assess the clinical utility of TMH Mini Quality of Life (TMQ) questionnaire	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	0.6	4 Years
Early detection programme for Oral, Breast and Cervical Cancer in Sangrur district of Punjab State	Dr. Atul Budukh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	31.14	5 Years 6 Months
A two arm randomized open label Phase II clinical trial to assess the efficacy of Gemcitabine-cisplatin or Capecitabine and Concurrent chemoradiation in Operated stage II & III GB cancer (GECCOR-GB)	Dr. Anant Ramaswamy	Zydus Non-Governmentceuticals, Dr. Reddy's Laboratories Limited	Non-Government	Medical & Health Sciences	2019	3.14	5 Years
Clinical effect of vaporized Cannabinoids on BREast cancer genetic EXpression patterns in the peri-operative period (CABREX study)	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	17.17	4 Years
A study of Low Dose Bevacizumab with conventional radiotherapy OR Ultra-Low Dose Radiotherapy alone in Diffuse Intrinsic Pontine Glioma. (LoBULaR-DIPG)	Dr. Rahul Krishnatry	Reliance Life Sciences Pvt Ltd + BRAIN TUMOR FUND	Non-Government	Medical & Health Sciences	2019	3.9	4 Years

Compilation of data as received from Dean-Academic of various CI's / oca of HBNI.

Protocol No. - 0328-17 : A single arm, multicentric, open label, efficacy and safety study of Docequalip (Docetaxel Lipid Suspension for Injection of Intas Non-Governmentceuticals Limited, India) based regimens in metastatic gastric adenocarcinoma patients	Dr. Vikas Ostwal	Intas Non-Governmentceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India.	Non-Government	Medical & Health Sciences	2019	23.51	3 Years 10 Months
A phase II study of hormone therapy alone in low-grade serous cancer (ovary/fallopian tube/peritoneum) following debulking surgery	Dr. Seema Gulia	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	4.25	6 Years
Prevalence of cardiovascular diseases in long term Breast Cancer survivors	Dr. Sheela Sawant	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3.44	6 Years
A prospective observational cohort study to identify the utility of risk-based screening strategy for long term complications in adolescent and adult cancer survivors of leukemia and lymphoma.	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	6.5	5 Years
Protocol No. - EGC002 : A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with Herceptin® as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer	Dr. Sudeep Gupta	Eirgenix Inc.	Non-Government	Medical & Health Sciences	2019	66	4 Years
Phase III, Assessor blinded, randomised controlled trial of the use of intraoperative neuromonitoring (IONM) in thyroid cancer surgery	Dr. Gouri Pantvaidya	TERRY FOX	Non-Government	Medical & Health Sciences	2019	6.02	5 Years
Evaluating The Role Of Genetic Susceptibility For Oropharynx Cancer In Indian Origin Population: a case-control study using the candidate gene approach	Dr. Sharayu Mhatre	ASCO (American Society of Cancer Oncology)	Non-Government	Medical & Health Sciences	2019	4.04	5 Years
Establishing an in house, cost effective, TMH Predict gene panel for Prognosis and Prediction in Breast Cancer Patients subjected to adjuvant therapy.	Dr. Omshree Shetty	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	4.3	5 Years
Phase III trial of Observation versus Irradiation for a gross totally resected grade II Meningioma	Dr. Tejal Gupta	NRG Oncology/RTOG	Non-Government	Medical & Health Sciences	2019	1.1	12 Years
Collaborative Action for Control of Cancer and Other Non-Communicable Diseases among Mumbai Police, Railway Police, Maharashtra Police and Maharashtra Security Force.	Dr. Gauravi Mishra	DAECTC + Tata Trusts	Non-Government	Medical & Health Sciences	2019	148.04	5 Years
A Prospective Phase III open label Randomized Controlled Trial evaluating the role of Neo-adjuvant chemotherapy in mandible preservation in oral cavity cancers	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	62.93	6 Years
Neoadjuvant treatment versus upfront surgery in Resectable pancreatic cancer (NEVUS)	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	14.88	5 Years
A double arm, phase-III randomised study to assess the effect of Resveratrol-Copper in reducing oral mucositis in patients receiving concurrent chemo-radiotherapy for locally advanced oral cavity and oropharyngeal cancers	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	10.31	5 Years

Compilation of data as received from
Dean-Academic of various CI's/Occ of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रसिद्ध विद्यालय परिसर, अणुशांती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

A Prospective Randomized Phase III Trial of Short Course Versus Long Course Local Radiotherapy in patients with Multiple Myeloma symptomatic for Pain (ProM)	Dr. Nehal Khanna	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	13.59	6 Years
PreCedeNT trial: Phase III randomised-controlled open-label trial of Lutetium - 177 Peptide Receptor Radionuclide Therapy (PRRT) Plus Chemotherapy Versus PRRT alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs)	Dr. Ameya Puranik	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3	8 Years
COMPARISON OF TREATMENT ADHERENCE AND TOXICITIES OF HIV POSITIVE PATIENTS VS. HIV NEGATIVE CERVICAL CANCER PATIENTS IN INDIA	Dr. Prachi Mittal	CRDF Global-ICMR	Non-Government	Medical & Health Sciences	2019	20.76	4 Years
Effect of nurse led intervention on cognitive and non-cognitive functions and serum TNF alpha levels in patients receiving chemotherapy for CRC at Tata Memorial Hospital, Mumbai	Mrs. Anita D Souza	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	3.53	4 Years 6 Months
Health expenditure on breast cancer treatment in women: a study from public sector tertiary cancer centre (EXPERT).	Dr. Tabassum Wadasadawala	WCI-NAG foundation	Non-Government	Medical & Health Sciences	2019	2	5 Years
Neuropathic pain in head and neck cancer patients referred to Specialist Palliative Care services: a cross sectional observational study.	Dr. Jayita Deodhar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	0.02	3 Years
Classical Hodgkins lymphoma (CHL) with primary marrow presentation- does it use immune escape mechanism to hide ?	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	6.12	1 Years
Randomised Trial comparing efficacy of Prophylactic versus Reactive Enteral Tube Insertion for Enteral Nutrition in Patients with Locally Advanced Head and Neck Carcinoma Treated with (Chemo)radiotherapy	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	5.23	5 Years
Prevalence and impact of Vitamin D deficiency on the treatment outcomes of Head and Neck squamous cell carcinoma patients.	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	7.5	4 Years
Protocol No. - D933GC00001 : A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)	Dr. Vikas Ostwal	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2019	14.43	4 Years
Evaluation of Organ filling (rectum and bladder) and Comprehensive Adaptive Radiotherapy using daily imaging by CBCT during radical radio(chemo)therapy for locally advanced cervical cancers.	Dr. Lavanya G	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	8.78	4 Years
Protocol No. - CLEE011A3201C : A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study	Dr. Sudeep Gupta	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical & Health Sciences	2020	90.2	5 Years
A Phase II Randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic non small cell lung cancer patients-TARGET-1	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2019	9.39	6 Years

Compilation of data as received from Dean
Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०१४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

A prospective observational study to compare speech and swallowing outcomes in patients undergoing treatment for oral tongue cancers	Dr. Shiva Kumar Thiagarajan	ICON	Non-Government	Medical & Health Sciences	2019	2.5	4 Years
Trastuzumab in HER2 positive Advanced Biliary tract cancers - single arm prospective phase II clinical trial (TAB trial)	Dr. Vikas Ostwal	Intramural and extramural grant (educational grant from Dr. Reddy's limited)	Non-Government	Medical & Health Sciences	2019	90.76	5 Years
Intra-operative recurrent laryngeal nerve monitoring during three field esophagectomy- a pilot study	Dr. Sabita Jiwnani	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	2.98	4 Years
Protocol No. - 20160372 : Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study	Dr. Bhausaheb Bagal	Amgen Inc	Non-Government	Medical & Health Sciences	2019	27.33	4 Years 11 Months
Protocol No. - E7080-M091-507 : Prospective Single Arm Post Marketing Phase IV study to assess the Safety and Efficacy of Lenvatinib in Subjects with Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer	Dr. Kumar Prabhash	Eisai Non-Government ceuticals India Pvt. Ltd.	Non-Government	Medical & Health Sciences	2019	7.55	4 Years 1 Months
A New Method for Cervical Cancer Screening in Low- and Middle-Income Countries (LMIC): Training and Technical Validation of Automated Visual Evaluation (AVE) in India	Dr. Rajesh Dikshit	Clinton Health Access Initiative (CHAI), USA	Non-Government	Medical & Health Sciences	2019	469.58	2 Years
Primary screening of high risk HPV DNA by a low cost molecular HPV test for early detection of cervical precancers and cancers among women in urban and rural community of Maharashtra	Dr. Sharmila Pimple	Department of Health Research (DHR)	Non-Government	Medical & Health Sciences	2019	23.14	4 Years
HEmodynamic Resuscitation and Monitoring in Early Sepsis (HERMES Study)	Dr. Sheila Myatra	ISCCM	Non-Government	Medical & Health Sciences	2019	0.4	2 Years 6 Months
Protocol No. - ALK18/ENZ124-CET1 : A prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN).	Dr. Kumar Prabhash	ALKEM LABORATORIES LIMITED	Non-Government	Medical & Health Sciences	2019	41.95	3 Years 10 Months
Protocol No. - QB46C-H03 : Exploratory Phase Ib/IIa Study of Intratumorally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Tumours	Dr. Gouri Pantvaidya	QBiotics Group Limited (QBiotics)	Non-Government	Medical & Health Sciences	2019	17.67	4 Years
Protocol No. - CLEE011A2207 : A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease	Dr. Sudeep Gupta	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical & Health Sciences	2020	22.08	4 Years
Comparative performance evaluation of Artificial Intelligence (AI) based visual inspection test (AI_VIA) with Primary Health Worker administered VIA (PHW_VIA), HPV DNA test and cervical cytology to detect cervical pre-cancer lesions.	Dr. Sharmila Pimple	Periwinkle Technologies Pvt. Ltd., Pune	Non-Government	Medical & Health Sciences	2019	2.23	3 Years

Compilation of data as received from Dean
Academic of various CI's/ OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशांक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - NIS/2018/19 : An open label, single arm, multicentric, observational study to evaluate safety and effectiveness of Akynzeo®, an oral fixed dose combination of netupitant and palonosetron in the management of CINV, in the real world settings of India	Dr. Sudeep Gupta	Glenmark Non-Governmentceutica ls Ltd.	Non-Government	Medical & Health Sciences	2020	4.17	2 Years 6 Months
Carboplatin / Paclitaxel Versus Cisplatin/ Etoposide as Definitive Chemoradiotherapy for LocoRegionally advanced Non small Lung cancer (NSCLC): A Phase III Randomized Controlled Trial	Dr. Ajaykumar Singh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	3.07	11 Years
Total Marrow and Lymphoid Irradiation (TMLI) as conditioning regimen for peripheral stem cell transplant in high risk/ relapsed /refractory leukemias.	Dr. Jayant Goda	Terry Fox	Non-Government	Medical & Health Sciences	2019	12.26	5 Years
Clinical outcome of common cancers treated with radical intent at HBCH Sangrur- A Retrospective Analysis	Dr. Jai Prakash Agarwal	University of Pennsylvania Philadelphia, US	Non-Government	Medical & Health Sciences	2019	8.25	2 Years
Phase 1 study of safety and feasibility of Ayurvedic oral cannabis preparation in the peri-operative period in breast and oral cavity squamous cell cancer	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	41.02	2 Years
Phase 3 non inferiority randomised study between low dose immunotherapy and cytotoxic chemotherapy in 2nd line or beyond setting in relapsed-recurrent or metastatic solid tumors	Dr. Rajendra Badwe	Trilokchand Papriwal Charitable Trust	Non-Government	Medical & Health Sciences	2020	66.26	5 Years
A two arm randomized open label prospective design superiority Phase II - III clinical trial to compare the efficacy of Docetaxel-oxaliplatin-capecitabine/ 5 fluorouracil (DOC/F) followed by Docetaxel versus Oxaliplatin-Capecitabine/5 fluorouracil (CAPOX/mFOLFOX-7) in advanced Gastric Cancers (DOC-GC)	Dr. Anant Ramaswamy	ASTRAZENECA Non- Government IND LTD / MERCK SPECIALITIES PVT LTD / DR. REDDYS LAB LTD / ELI LILLY AND COMP IND PVT LTD / ICON TRUST / NAG FOUNDATION / MANKIND Non- Government LTD	Non-Government	Medical & Health Sciences	2020	21.87	4 Years 6 Months
Protocol No. - MK3475-593 : A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma or PD-L1 positive Non-Small Cell Lung Cancer (NSCLC) in India (Keynote-593)	Dr. Jyoti Bajpai	MSD Non- Governmentceutica ls Pvt Ltd	Non-Government	Medical & Health Sciences	2020	91.22	5 Years
An open label, prospective three-arm randomized, non-comparative study on efficacy and tolerability of orally disintegrating strip, oral tablets and intravenous administration of Vitamin B12, in post-gastrectomy Indian patients	Dr. Sridhar Sundaram	EISAI Non- Government CEUTICALS, INTAS	Non-Government	Medical & Health Sciences	2020	6.39	6 Years
Protocol No. - DRL-INDG02-PAN/2018 : An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize its Safety, Tolerability and Activity in Indian Subjects with Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer	Dr. Vikas Ostwal	Dr. Reddy's Laboratories Ltd.	Non-Government	Medical & Health Sciences	2020	8.96	3 Years

Compilation of data as received from Dean-
Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशांक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Adjuvant chemotherapy for operated amPullary AdenoCarcinomas based on Histology and Intensification ; A two arm non - randomized open label prospective parallel adaptive design phase II clinical trial (APACHI)	Dr. Anant Ramaswamy	Educational Grant - Reliance Life Science / DAECTC	Non-Government	Medical & Health Sciences	2020	1.6	7 Years
A randomized study to evaluate the effectiveness of Gabapentin on Oral-Mucositis induced pain due to chemo-radio therapy in patients with head and neck cancers.	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	4.24	5 Years
A phase II study to evaluate the role of short-course Pomalidomide in maintaining treatment-free remission post tyrosine-kinase inhibitor (TKI) discontinuation in adult patients with chronic myeloid leukemia-chronic phase (CML-CP).	Dr. Hasmukh Jain	Unrestricted grants educational grants from Non-Government companies	Non-Government	Medical & Health Sciences	2020	33.38	6 Years 6 Months
A clinical study to evaluate the safety and feasibility of outpatient induction therapy in newly diagnosed adolescent and adult acute myeloid leukemia (AML).	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	4.71	3 Years
A study evaluating the efficacy of axillary reverse mapping in biopsy proven patients undergoing upfront surgery.	Dr. Vani Parmar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	0.73	4 Years
A randomized trial to assess the effect of Oral Cryotherapy in prevention of mucositis in head and neck cancer patients receiving Chemo-Radiotherapy	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	3.36	5 Years
Treatment and monitoring of children and adolescents with Chronic Myeloid Leukemia (CML)- A prospective observational study.	Dr. Nirmalya Mouluk	SOHN foundation through GRAVIS	Non-Government	Medical & Health Sciences	2020	3.34	5 Years
Epithelial-mesenchymal transition (EMT) and Breast Cancer Stemness: Defining the role of OVOL and ACTN4 in cross talk	Dr. Omshree Shetty	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	8.71	3 Years
Grid Oncology: Remaking Cancer Care in India	Dr. C. S. Pramesh	Wellcome Trust	Non-Government	Medical & Health Sciences	2020	7.59	4 Years
Study of the excess cost associated with drug wastage due to limited vial size options of the intravenous drugs for anti-cancer treatment, among patients receiving such treatment at Tata Memorial Hospital - 'CADWIACT' study	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	0.17	3 Years 6 Months
An open label, randomized, clinical trial of Mycobacterium w (Mw) as an Adjuvant to chemotherapy in Advanced Non-small Cell Lung Cancer	Dr. Kumar Prabhash	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	32.44	6 Years
Standard Maintenance Therapy versus Local Consolidation Radiation Therapy and Standard Maintenance Therapy In 1-5 sites of oligometastatic Non-Small Cell Lung Cancer (NSCLC) - A Phase III Randomized Controlled Trial (TARGET-2)	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	10.13	6 Years
To assess the efficacy of low dose Abiraterone (250 mg (1 tablet) once daily taken along with food) in comparison to the standard dose Abiraterone (1000 mg (4 tablets) taken in fasting state) in patients with Metastatic Castrate Resistant Prostate Cancer.	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	7.27	5 Years
A Prospective Observational Study on Outcomes of Bone Metastases treated with Radiotherapy in Lung Cancer	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	3.56	5 Years
A prospective study to assess the effect of peri operative administration of oral Resveratrol and copper(R- Cu)on survival in Glioblastoma (GBM) patients.	Dr. Aliasgar Moiyadi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	4.53	5 Years
Indian Pulmonary Embolism Registry (IndiPER)	Dr. Sohan Solanki	ETERNAL HOSPITAL JAIPUR	Non-Government	Medical & Health Sciences	2020	0.05	3 Years

Compilation of data as received from
Dean-Academic of various CI's/OCC of HBNI.

A randomized, open label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with standard triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy induced Nausea and vomiting in subjects with osteosarcoma and other solid tumors (OLAnzaPINE)	Dr. Jyoti Bajpai	PROGRESSIVE LADIES WELFARE SOCIETY (NGO)	Non-Government	Medical & Health Sciences	2020	1.32	4 Years
Capecitabine and Erlotinib in advanced Hepatocellular Carcinoma (HCC) after Sorafenib failure (CAPER- HCC study) - a single arm, prospective phase II clinical trial.	Dr. Prabhat Bhargava	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	16.69	2 Years 6 Months
Phase I study to evaluate the feasibility and safety of addition of ruxolitinib to a standard BFM-90 regimen in adolescent/adult Ph-like ALL.	Dr. Hasmukh Jain	EM- LADY TATA MEMORIAL TRUST	Non-Government	Medical & Health Sciences	2020	18.74	4 Years
A study to validate the Multinational Association of Supportive Care in Cancer (MASCC) antiemesis tool for adolescent and adult patients with hematological malignancies receiving chemotherapy.	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	0.08	3 Years 6 Months
Improving the efficiency of Breath-hold treatment in cancer radiotherapy using 3D goggles: a randomized study	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	2.44	4 Years
Focal Radiotherapy Plus Low-Dose Craniospinal Irradiation Followed By Adjuvant Chemotherapy In WNT Subgroup Medulloblastoma (FOR-WNT 2 Study)	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	3.75	10 Years
Pregabalin for chronic cough in patients with lung cancer: A randomized double-blind placebo-controlled trial.	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	4.19	3 Years
Observation or upfront cranial RT in oncogene driver mutated NSCLC with asymptomatic brain metastases: A phase III Randomized Controlled Trial	Dr. Anil Tibdewal	Intramural and EM-NEUROONCOLOGY RESEARCH FUND	Non-Government	Medical & Health Sciences	2020	14.27	6 Years
Whole brain radiation therapy plus Resveratrol-Copper in brain metastases patients of non small cell lung cancer - A Phase II Randomized controlled trial.	Dr. Jai Prakash Agarwal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	7.34	6 Years 6 Months
Protocol No. - D0816R00025 : A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation (SOLI Study)	Dr. Sudeep Gupta	AstraZeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2020	49.22	3 Years
Protocol No. - TX05-03E : A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03	Dr. Sushmita Rath	Tanvex Biologics Corp.	Non-Government	Medical & Health Sciences	2020	58.12	2 Years
Genomic Profiling of SARS-CoV-2 Infection in the city of Mumbai	Dr. Nikhil Patkar	ACTREC	Non-Government	Medical & Health Sciences	2020	8.77	2 Years
Protocol No. - D3614C00001 : A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC).	Dr. Sudeep Gupta	AstraZeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2020	136.38	4 Years 4 Months

Compilation of data as received from Dean-Academic of Various CI's/occe of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०१४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Seroprevalence of COVID-19 in slum and non slum areas of Mumbai	Dr. Rajesh Dikshit	i-spirit	Non-Government	Medical & Health Sciences	2020	201.01	3 Months
Intravesical BCG: is the urinary bladder ready to receive it?	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	10.79	2 Years
A phase II randomized study to evaluate the efficacy of short-course RR CVEP regimen against short course EPOCH-RR in adolescent and adult seropositive Diffuse large B cell lymphoma	Dr. Manju Sengar	TRAC and Unrestricted Educational grants from Non-Government companies AND DONORS	Non-Government	Medical & Health Sciences	2020	34.91	4 Years
A pilot study of indigenously manufactured HCAR19 (2nd generation Anti-CD19-41BBCD3 (zeta) chimeric antigen receptor T-cell therapy) in adult patients with relapsed/refractory diffuse large B-cell lymphoma.	Dr. Hasmukh Jain	Intramural and Extramural-Immunoadoptive cell therapy private limited, ICMR	Non-Government	Medical & Health Sciences	2020	7.95	9 Years 11 Months
Angiotensin receptor blockade with losartan plus mFOLFIRINOX versus mFOLFIRINOX alone in advanced Pancreatic AdenoCarcinomas - a two arm open label prospective Phase III parallel design randomized superiority clinical trial (AFPAC)	Dr. Anant Ramaswamy	EM - LUPIN PVT LTD	Non-Government	Medical & Health Sciences	2021	4.85	7 Years
PIK3CA Registry- A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer.	Dr. Sudeep Gupta	NOVARTIS HEALTHCARE PRIVATE LIMITED	Non-Government	Medical & Health Sciences	2020	4.88	2 Years
Prospective study to evaluate which method of estimated GFR best predicts for measured GFR in patients with ovarian cancer undergoing carboplatin based chemotherapy .	Dr. Jaya Ghosh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	0.79	3 Years
A Double Blind Placebo Controlled Randomized Trial On Oral Cannabidiol For Chronic Cancer Pain Relief	Dr. Aparna Chatterjee	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	4.98	2 Years
Posterior fossa Ependyomas: a study on molecular subgrouping	Dr. Sridhar Epari	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2020	13.99	2 Years
Protocol No. - D933AC00001 : A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)	Dr. Vikas Ostwal	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2020	29.65	4 Years
A prospective, multicentre, post-marketing phase IV study to assess the safety and efficacy of Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC)	Dr. Vikas Ostwal	Eisai Non-Governmentceuticals, India Pvt. Ltd. 6th Floor, A Wing, Marwah Center, Krishanlal Marwah Marg, Andheri East, Mumbai 400072. Maharashtra, INDIA. Phon	Non-Government	Medical & Health Sciences	2021	3.13	3 Years

Compilation of data as received from Dean-
Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमो भाषा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०१४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Influence of Preoperative Vitamin-D, Serum Magnesium and Serum Phosphate levels on the development of transient and permanent hypocalcaemia and hypoparathyroidism following total thyroidectomy with or without central compartment clearance in patients with thyroid cancer (HypoCal Study).	Dr. Shiva Kumar Thiagarajan	RESEARCH A/C 4254	Non-Government	Medical & Health Sciences	2020	4.58	4 Years
Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia: the COVID STEROID 2 trial	Dr. Jigeeshu Divatia	The George Institute for Global Health Plot No. 57, Second Floor, Corporation Bank Building Nagarjuna Circle, Punjagutta, Hyderabad - 500 082, Telanga	Non-Government	Medical & Health Sciences	2020	3	2 Years
Primary Surgery versus Primary Chemo-radiation for Oropharyngeal Cancer (SCOPE trial) - A Phase II/III Integrated Design Randomized Control Trial	Dr. Deepa Nair	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	22.81	6 Years 11 Months
A Randomized Study to compare Gefitinib to Gefitinib with Chemotherapy in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients with Compromised Performance Status.	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	27.16	4 Years
Protocol No. - ALK19/ENZ137-BEV1 : A prospective, multicenter, randomized, double blind, Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. versus Innovator Bevacizumab both in Combination with CAPEOX in Patients with Metastatic Colorectal Cancer.	Dr. Vikas Ostwal	Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, Enzene Biosciences Limited, Plot Number	Non-Government	Medical & Health Sciences	2021	4.39	3 Years 4 Months
Protocol No. - D133HC00003 : A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC)	Dr. Nandini Menon	AstraZeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2021	22.76	3 Years 6 Months
Protocol No. - D9106C00001 : A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)	Dr. C. S. Pramesh	AstraZeneca AB	Non-Government	Medical & Health Sciences	2021	9.5	7 Years
Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic phase chronic myeloid leukemia - A multi-center phase II single arm study	Dr. Hasmukh Jain	Hematology Cancer Consortium	Non-Government	Medical & Health Sciences	2021	4.22	3 Years

Compilation of data as received from Dean-
Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशांक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - 61186372NSC3001 : A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20Ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.	Dr. Vanita Noronha	Johnson and Johnson Private Limited	Non-Government	Medical & Health Sciences	2021	22.79	3 Years 6 Months
TMH IRIS: Proposal for participation of TMH ICU in the Indian Registry of IntenSive care (IRIS)	Dr. Atul Kulkarni	Chennai Critical Care Consultants Group	Non-Government	Medical & Health Sciences	2021	0.22	12 Years
Protocol No. - 73841937NSC3003 : A Phase 3, Randomized study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated LocallyAdvanced or Metastatic Non-Small Cell Lung Cancer	Dr. Kumar Prabhash	Johnson & Johnson Private Limited	Non-Government	Medical & Health Sciences	2021	32.6	3 Years 6 Months
A Phase 4 Study of Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk Factors Conducted in India	Dr. Amit Joshi	Bristol-Myers Squibb Research and Development	Non-Government	Medical & Health Sciences	2021	33.69	3 Years
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)	Dr. Swapnil Rane	NIH	Non-Government	Medical & Health Sciences	2021	26.19	5 Years
Prophylactic pirfenidone for prevention of radiation induced pneumonitis in patients with Lung cancer (PROPER study)	Dr. Naveen Mummudi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	0.33	3 Years
PIK3CA mutation prevalence and clinico-pathological association in breast carcinomas	Dr. Sangeeta Desai	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	7.01	2 Years 6 Months
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2).	Dr. Vikas Ostwal	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2021	22.19	3 Years
CDKN2A deletion in IDH-mutant diffuse astrocytic tumors	Dr. Sridhar Epari	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	5.36	2 Years
Evaluating Immunohistochemical and Molecular Landscape of Select Osteoclastic Giant Cell Rich Tumors of the Bone	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	4.13	3 Years
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02).	Dr. Vikas Ostwal	AstraZeneca Non-Government India Ltd	Non-Government	Medical & Health Sciences	2021	6.24	3 Years
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)	Dr. C. S. Pramesh	Astrazeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2021	12.61	6 Years
Evaluation of the effect of foot bathing on peripheral neuropathy in patients receiving oxaliplatin containing chemotherapy for GI cancer at Tata Memorial Hospital	Mrs. Anita D Souza	IASCC	Non-Government	Medical & Health Sciences	2021	0.8	3 Years
Early T-cell precursor acute lymphoblastic leukaemia: Unravelling mechanisms of resistance and development of novel therapeutic strategies	Dr. Manju Sengar	Lady Tata Memorial Trust	Non-Government	Medical & Health Sciences	2021	49.46	4 Years

Compilation of data as received from
Dean - Academic of various CI's/Occ of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशास्त्री नगर, मुंबई - ४०० ०१४
Training School Complex, Anushakti Nagar, Mumbai - 400 014

Effect of topical coconut oil application versus standard supportive care on xerostomia related quality of life among patients with radiation induced xerostomia in H& N cancer patients in tertiary care cancer center- A randomized control trial	Mrs. Meera Achrekar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	0.2	3 Years 10 Days
Enhanced Recovery Pathway in Head and Neck Cancer Surgery	Dr. Vandana Agarwal	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	2.47	3 Years
National Quality Assurance (NQA) program in Biochemistry for Electrophoresis, Immunofixation and Tumor markers in centers of the National Cancer Grid	Dr. Kinjalika Ghosh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	20.17	3 Years
A phase I study of oral metronomic capecitabine with cyclophosphamide as maintenance therapy in patients with chemotherapy responsive advanced colorectal cancers .	Dr. Anant Ramaswamy	RESEARCH A/C 4254	Non-Government	Medical & Health Sciences	2021	22.62	2 Years 6 Months
Protocol No. - D967JC00001 : A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)	Dr. Sudeep Gupta	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences,	2021	48.05	3 Years
PROspective Study on the use of gEriatric assessment Tools for validation of 1-year mortality in breast cancer patients 65 years and older (PROTECT)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	3.4	3 Years
Avoiding prophylactic growth factors during paclitaxel phase of dose dense adjuvant chemotherapy in breast cancer	Dr. Seema Gulia	Indian Association of Supportive Care	Non-Government	Medical & Health Sciences	2021	1.5	2 Years
Assessment of the Breast Cosmesis using Deep neural networks: an exploratory study (ABCD)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	17.37	3 Years
Pilot study for measurement of intra-tumoral interstitial fluid pressure in various cancers	Dr. Shalaka Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	17.92	3 Years
Arsenic trioxide (ATO) plus FOLFIRI vs. Irinotecan monotherapy as second-line therapy in advanced Colorectal Cancers - a randomized non-blinded two-arm Phase II prospective (ATaCC study).	Dr. Prabhat Bhargava	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	7.59	5 Years
Prevalence, predisposing factors and management of Head and Neck Lymphedema in patients following treatment for Head and Neck Cancer. (HeNly-1 Study)	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	2.06	4 Years
Protocol No. - D9311C00001 : A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)	Dr. Sudeep Gupta	AstraZeneca	Non-Government	Medical & Health Sciences	2021	50.21	4 Years
An open label phase III randomized clinical trial of pomalidomide cyclophosphamide and dexamethasone versus pomalidomide dexamethasone in relapsed/ refractory multiple myeloma treated with lenalidomide and a proteasome Inhibitor.	Dr. Lingaraj Nayak	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	5.51	3 Years 10 Months

Compilation of data as received from Dean-Academic of various CI's/OCC of HBNI.

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Dr. Badira Parambil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	5.35	10 Years
A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)	Dr. C. S. Pramesh	Astrazeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2021	8.48	7 Years 6 Months
The Clinical Value of Ultrasound based Navigation update in cranial resection procedures	Dr. Aliasgar Moiyadi	Brainlab AG	Non-Government	Medical & Health Sciences	2021	11.08	3 Years
Pilot testing of Hindi and Marathi translations of the European Organization for the Research and Treatment of Cancer (EORTC) module, assessing quality of life in patients with primary vulva cancer (EORTC QLQ VU34).	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	0.05	2 Years
A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors(NAVIGATE)	Dr. Vikas Ostwal	Non-US: Bayer Consumer Care AG, Peter-Merian-Strasse 84, 4052 Basel, Switzerland US-territory: Bayer HealthCare Non-Governmentceuticals Inc., 100 Bayer Boule	Non-Government	Medical & Health Sciences	2021	17.08	3 Years
A randomized phase III clinical trial evaluating the non-inferiority of reduced dose chemotherapeutic regimens based on CARG risk scores compared to standard doses in Older patients with advanced esophageal, esophagogastric, gastric, and biliary tract cancers (CARGO study)	Dr. Anant Ramaswamy	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	10.02	6 Years
Preventing Cervical Cancer in India through self-sampling (PCCIS)	Dr. Gauravi Mishra	Fund for Innovation and Transformation, program of the Inter-Council Network of Provincial and Regional Councils (ICN), Global Affairs Canada.	Non-Government	Medical & Health Sciences	2021	43.96	1 Years 9 Months
Protocol No. - D8220C00022 : A prospective, multi-centre, phase IV clinical trial to assess the safety and efficacy of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukemia and relapsed and refractory mantle cell lymphoma	Dr. Manju Sengar	AstraZeneca Non-Government India Limited	Non-Government	Medical & Health Sciences	2021	14.72	2 Years
Impact of on-demand training & audio-visual aids to improve referral rates for genetic counselling and/ testing at a tertiary cancer centre (Mainstreaming Study)	Dr. Rima Pathak	Astra Zeneca	Non-Government	Medical & Health Sciences	2022	5	2 Years

Compilation of data as received from Dean-Academic of various CI's/oc of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

A Multicountry, Multicentre, Non-interventional, Prospective Study to Determine the Prevalence of EGFR Mutations in Patients with Early-stage, Surgically Resected, Non-squamous, Non-small Cell Lung Cancer	Dr. Kumar Prabhash	Astra Zeneca Non-Government India Ltd	Non-Government	Medical & Health Sciences	2022	1.5	2 Years
Immunohistochemical analysis of LLT1 on prostate cancer biopsy samples	Dr. Santosh Menon	Zumutor Biologics	Non-Government	Medical & Health Sciences	2021	2.29	2 Years
Women Empowerment-Cancer Awareness Nexus (WE-CAN): An Implementation Research Study of Cervical Cancer Prevention through HPV Self-Sampling and Education in India	Dr. Gauravi Mishra	Indian Medical Council of Research (ICMR) & Canadian Institutes of Health Research (CIHR) under Global Alliances for Chronic Diseases(GACD)	Non-Government	Medical & Health Sciences	2021	314.3	5 Years
An Open-label, Multicenter, Randomized Phase 3 Study of First line Encorafenib Plus Cetuximab With or Without Chemotherapy versus Standard of Care Therapy with a Safety Lead-in of Encorafenib and Cetuximab Plus Chemotherapy In Participants with Metastatic BRAF V600E Mutant Colorectal Cancer	Dr. Vikas Ostwal	PFIZER	Non-Government	Medical & Health Sciences	2021	20.29	3 Years
PRESCRIP-TEC Prevention and Screening Innovation Project Toward Elimination of Cervical Cancer	Dr. Sharmila Pimple	Horizon 2020-DBT	Non-Government	Medical & Health Sciences	2021	25.19	3 Years
Protocol No. - WO42633 : Protocol No. - WO42633 : A Phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for HER2-positive breast cancer at high risk of recurrence following preoperative therapy (ASTEFANIA STUDY).	Dr. Sudeep Gupta	Roche Products (India) Pvt. Ltd.	Non-Government	Medical & Health Sciences	2022	50.52	10 Years
Protocol No. - MO42921 : A MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY TO EVALUATE THE PREVALENCE OF PD-L1 AND ITS ROLE IN PATIENTS WITH TNBC TREATED WITH SYSTEMIC THERAPY (VANESSA)	Dr. Sudeep Gupta	Roche Products India Pvt Ltd.	Non-Government	Medical & Health Sciences	2022	13.9	2 Years
Protocol No. - DP-1111-02CT : A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of Gastroenteric or Pancreatic Origin (COMPOSE)	Dr. Venkatesh Rangarajan	ITM Solucin GmbH	Non-Government	Medical & Health Sciences	2022	37.78	2 Years 10 Months 1 Days
Developing precision immunotherapy for value-based treatment of lung cancer in India	Dr. C. S. Pramesh	DBT/Wellcome Trust india Alliance	Non-Government	Medical & Health Sciences	2021	199.82	5 Years

Compilation of data as received from Dean.
Academia of various CI's/ OCC of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०१४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

GUT MICROBIOME IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - ASSOCIATION WITH LEUKEMOGENESIS, SERIAL SURVEILLANCE AND EFFECT ON TOXICITY, DISEASE OUTCOME AND IMMUNOLOGICAL RECOVERY	Dr. Nirmalya Moulik	LADY TATA MEMORIAL TRUST	Non-Government	Medical & Health Sciences	2022	34.59	3 Years
Protocol No. - ACE-LY-312(D8227C00001) : A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects <= 75 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma	Dr. Bhausheeb Bagal	AstraZeneca Canada Inc.	Non-Government	Medical & Health Sciences	2022	22.53	8 Years
Protocol No. - GO42784 : A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer	Dr. Sudeep Gupta	Hoffmann-La Roche Ltd	Non-Government	Medical & Health Sciences	2022	52.09	10 Years
PErioperative respiratory care and outcomes for patieNts Undergoing hIgh risk abdomiNal surgery	Dr. Sohan Solanki	University of Birmingham	Non-Government	Medical & Health Sciences	2022	0.9	2 Years
Protocol No. - D0817R00044 : A non-interventional, multicenter study to determine the prevalence of homologous recombination repair.(HRR) gene mutation in patients with metastatic castration-resistant prostate cancer in India	Dr. Nandini Menon	AstraZeneca Non-Government India Ltd.	Non-Government	Medical & Health Sciences	2022	7.5	1 Years 6 Months
Developing a 3D-printed Humanoid Phantom for Breast Cancer Radiotherapy Dosimetry and Quality Assurance	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	0.18	2 Years
A Multi-country, Multi-centre, Non-interventional, RETrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant PROstate Cancer.	Dr. Amit Joshi	AstraZeneca	Non-Government	Medical & Health Sciences	2022	8.65	1 Years
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure	Dr. Ajaykumar Singh	Janssen	Non-Government	Medical & Health Sciences	2022	23.7	3 Years
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Safety And Efficacy Of PolatuzumabVedotin In Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-Gemox) Versus R-Gemox Alone In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Dr. Manju Sengar	Roche Products (India) Private Limited	Non-Government	Medical & Health Sciences	2022	9.92	3 Years
Molecular profiling of malignant brain tumors using CSF derived circulating tumor DNA	Dr. Tejpal Gupta	Strand Life Sciences Pvt. Ltd.	Non-Government	Medical & Health Sciences	2022	4.62	2 Years
Protocol No. - D419CR00025 : A Multicountry, Multicentre, Noninterventional, Retrospective Study to Describe the Real-world Management Outcomes in Patients With Unresectable Hepatocellular Carcinoma	Dr. Vikas Ostwal	Sponsor : AstraZeneca Non-Government India Ltd	Non-Government	Medical & Health Sciences	2022	1.12	2 Years
Identifying potentially metastatic cells in primary tissue by identifying specific proteins associated with these phenotypes using an antibody library based screening of TNBC.	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	31.87	2 Years

Compilation of data as received from Dean-Academic of various CI's/ oca of HBNI.

Protocol No. - D967SC00001 : An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)	Dr. Nandini Menon	Astrazeneca Pvt Ltd	Non-Government	Medical & Health Sciences	2022	10.34	6 Years
Multiparametric brain mapping integrating structural, functional and biological features and correlation with functional and oncological outcomes (BrainMap Study)	Dr. Aliasgar Moiyadi	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	73.3	3 Years
Prospective PeriOperative study Evaluating Routine Coagulation versus Thromboelastography for Liver resections (PORTAL 2 Trial)	Dr. Reshma Ambulkar	TRAC (TMC research administration council)	Non-Government	Medical & Health Sciences	2022	0.99	1 Years
Validation of the Caregiver Burden Scale & assessment of caregiving burden of parents of children with advanced cancer at a tertiary care set-up in India	Dr. Jayita Deodhar	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2023	4.5	2 Years
A multicenter retrospective study on the prognostic impact of pregnancy in women with history of BRCA mutated breast cancer.	Dr. Jyoti Bajpai	TMH AND Institut Jules Bordet	Non-Government	Medical & Health Sciences	2022	1.32	2 Years
Protocol No. - CA-170-302 : A Phase IIb/III, Randomised, Double-blind, Placebo-controlled, Multicentre, Study of CA-170 in Combination with Chemotherapy in Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer (ASIAD-3).	Dr. Nandini Menon	Aurigene Discovery Technologies Limited	Non-Government	Medical & Health Sciences	2022	68.24	10 Years
Evaluation of Saragene HPV -HR test kit and its comparison with Cobas 4800 HPV test kit for detection of High-Risk genotypes of Human Papillomavirus.	Dr. Gaurav Salunke	Cosara Diagnostics Pvt Ltd	Non-Government	Medical & Health Sciences	2022	2.07	6 Months
Early Detection of Common Cancers among Women in India	Dr. Rajendra Badwe	National Institute Of Health, USA	Non-Government	Medical & Health Sciences	1996	40.81	26 Years
Supply of graphite electrode based plasma torch assembly for generating 25KW Plasma arc at 50V and 500A	Dr. Vishal Jain	Gujtex Engineering Company	Non-Government	Engineering Sciences	2022	3.3	8 months
eLife Ben Barres Spotlight Award fund	Dr. Swagata Ghatak	Ben Barres Spotlight Award fund	Non-Government	Life Science	2023	1.66	3 years
Beyond Standard Model Physics with Neutrino and Dark Matter at Energy, Intensity and Cosmic Frontiers	Dr. Manimala Mitra	Centre Franco-Indian Pour la Promotion De La Recherche A Vancee	Non-Government	Physical Sciences	2020	4.75	3 years
Supply of DBD based plasma system	Mr. Chirayu Patil	Institute of Pharmacy, Nirma University	Non-Government	Engineering Sciences	2022	4.3	3 months

Compilation of data as received from
Dean-Academic of various CI's/OCC of
HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Basic Research in Nuclear and High Energy Physics: Development and installation of fast timing photon spectrometer, magnetic spectrometers for electrons and recoils	Akashrup Banerjee	DAE	Government	Physical Science	2019	20	5 Years
Basic Research in Nuclear and High Energy Physics: Study capture reactions, perform gamma spectroscopy and neutron activation studies through in-beam real time exposures and offbeam irradiation exposures.	Anjali Mukherjee	DAE	Government	Physical Science	2019	76	5 Years
Basic Research in Nuclear and High Energy Physics: Establishing FPGA programming and training laboratory	Arindam Das	DAE	Government	Physical Science	2019	12	5 Years
Basic Research in Nuclear and High Energy Physics: Basic research in theoretical physics in the fields of Beyond the Standard Model Physics, Strings, Gravity and Math Physics, Hot and Dense Matter in terrestrial and celestial labs. Particle nature of Dark Matter, Neutrino physics and	Arnab Kundu	DAE	Government	Physical Science	2019	0.2	5 Years
Basic Research in Nuclear and High Energy Physics: Setting up the experimental facilities at the surface and underground laboratories at IUSL	Debashis Das	DAE	Government	Physical Science	2019	0.4	5 Years
Basic Research in Nuclear and High Energy Physics: Study of the level of radioactivity, the cosmogenic and radiogenic neutron backgrounds at IUSL and to develop methods of mitigating those backgrounds.	Maitrayee Nandi	DAE	Government	Physical Science	2019	58.2	5 Years
Basic Research in Nuclear and High Energy Physics: Detector development for Dark Matter search experiment and observational TeV gamma-ray astronomy	Mala Das	DAE	Government	Physical Science	2019	54.8	5 Years
Basic Research in Nuclear and High Energy Physics: Setting up the experimental facilities at the surface and underground laboratories at IUSL	Manoj Saran	DAE	Government	Physical Science	2019	90.8	5 Years
Basic Research in Nuclear and High Energy Physics: Molecular Beam Spectroscopy Laboratory to perform Vibrational Mediated Photo-dissociation (VMP) of atoms, molecules and clusters.	Montu K. Hazra	DAE	Government	Physical Science	2019	78.8	5 Years
Basic Research in Nuclear and High Energy Physics: Development of muon telescope for naturally abundant cosmic muon based tomography	Nayana Majumdar	DAE	Government	Physical Science	2019	25.8	5 Years
Basic Research in Nuclear and High Energy Physics: Theoretical and Experimental investigations of the Multiwavelength and the Multi-messenger Astroparticle Physics.	Pratik Majumdar	DAE	Government	Physical Science	2019	13.4	5 Years
Basic Research in Nuclear and High Energy Physics: Storage and retrieval of light pulses in cold and hot atomic medium using coherent manipulation of photons	Sankar De	DAE	Government	Physical Science	2019	45.6	5 Years
Basic Research in Nuclear and High Energy Physics: Installation of a facility for compute-clusters and development of scientific software in advanced areas of theoretical research.	Subir Sarkar	DAE	Government	Physical Science	2019	149.4	5 Years
Basic Research in Nuclear and High Energy Physics: Development of muon telescope for naturally abundant cosmic muon based tomography	Supratik Mukhopadhyay	DAE	Government	Physical Science	2019	9.2	5 Years

Compilation of data as received from.
Dean-Academic of various CI's/OCC of HBNI.

प्रो. पी. सी. सेल्विन / REGISTRAR
कुलसचिव / REGISTRAR
होमो भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशासन विद्यालय परिसर, अनुशासकीय नगर, मुंबई - ४०० ९९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094.

Basic and applied research in Biophysics and Material sciences: Study of structural changes of the nanomaterials using Indus-II synchrotron source at RRCAT, Indore	Satyaban Bhunia, Mrinmay Mukhopadhyay	DAE	Government	Physical Sciences	2019	50	5 Years
Basic and applied research in Biophysics and Material sciences: Study of topography, structure and composition of soft and hard LD systems	Satyajit Hazra, Mrinmay Mukhopadhyay	DAE	Government	Physical Sciences	2019	20	5 Years
Basic and applied research in Biophysics and Material sciences: Understanding in-plane and out-of-plane structure and evolution of LD systems in a non-destructive way	Satyajit Hazra, Mrinmay Mukhopadhyay	DAE	Government	Physical Sciences	2019	30	5 Years
Basic and applied research in Biophysics and Material sciences: Study of optoelectronic properties of low dimensional systems	Satyaban Bhunia	DAE	Government	Physical Sciences	2019	12	5 Years
Basic and applied research in Biophysics and Material sciences: Study of high performance thermoelectric, magneto-caloric, magneto-resistive materials etc	Indranil Das, Chandan Mazumdar	DAE	Government	Physical Sciences	2019	30	5 Years
Basic and applied research in Biophysics and Material sciences: Study of spin/quantum electronics including switching devices	Indranil Das	DAE	Government	Physical Sciences	2019	23	5 Years
Basic and applied research in Biophysics and Material sciences: Large scale simulation of complex materials	Avik Basu, Arti Garg and Kalpataru Pradhan	DAE	Government	Physical Sciences	2019	22	5 Years
Basic and applied research in Biophysics and Material sciences: Study of low dimensional energy harvesting materials	Biswarup Satpati	DAE	Government	Physical Sciences	2019	6	5 Years
Basic and applied research in Biophysics and Material sciences: Spectroscopic characterization of low dimensional structures	K. S. R. Menon	DAE	Government	Physical Sciences	2019	14	5 Years
Basic and applied research in Biophysics and Material sciences: Demonstration of next-generation coherent electronics based on topologically protected states	Biswajit Karmakar	DAE	Government	Physical Sciences	2019	60	5 Years
Basic and applied research in Biophysics and Material sciences: Study of large local/non-local magnetoresistance and topological properties	Indranil Das	DAE	Government	Physical Sciences	2019	4	5 Years
Basic and applied research in Biophysics and Material sciences: Study of exotic materials by positron annihilation	P. M. G. Nambission	DAE	Government	Physical Sciences	2019	6	5 Years
Basic and applied research in Biophysics and Material sciences: Investigation of semiconductor micro-nano devices	Supratic Chakraborty	DAE	Government	Physical Sciences	2019	9	5 Years
Basic Research in Nuclear and High Energy Physics: Utilization and upgradation of a national accelerator facility for research in nuclear astrophysics (FRENA)	Chinmay Basu	DAE	Government	Physical Science	2019	112.4	5 Years

Compilation of data as received from Dean.
Academic of various CI's/Occ of HBNI.

प्र. पी. सी. सेल्विन / REGISTRAR
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
श्रीराम विद्यालय परिसर, अणुशक्ती नगर, मुंबई - 400 094
School Complex, Anushakti Nagar, Mumbai - 400 094

Basic Research in Nuclear and High Energy Physics: Study of unusual properties of exotic nuclei far from beta stability using International RIB facilities	Ushasi Dutta	DAE	Government	Physical Science	2019	100	5 Years
--	--------------	-----	------------	------------------	------	-----	---------

Compilation of data as received from Dean-Academic of various
CI's/Occ of HBNI.


 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अनुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094